<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Lipid‐lowering agents for nephrotic syndrome - Kong, X - 2013 | Cochrane Library</title> <meta content="Lipid‐lowering agents for nephrotic syndrome - Kong, X - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005425.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Lipid‐lowering agents for nephrotic syndrome - Kong, X - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005425.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD005425.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Lipid‐lowering agents for nephrotic syndrome" name="citation_title"/> <meta content="Xiangyu Kong" name="citation_author"/> <meta content="Chengdu Medical College" name="citation_author_institution"/> <meta content="Hao Yuan" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Junming Fan" name="citation_author"/> <meta content="Luzhou Medical College" name="citation_author_institution"/> <meta content="Zi Li" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Taixiang Wu" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="txwutx@hotmail.com" name="citation_author_email"/> <meta content="Lanhui Jiang" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD005425.pub2" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/12/10" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005425.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005425.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005425.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Fatty Acids, Monounsaturated [therapeutic use]; Fluvastatin; Gemfibrozil [therapeutic use]; Hydroxymethylglutaryl‐CoA Reductase Inhibitors [therapeutic use]; Hypolipidemic Agents [therapeutic use]; Indoles [therapeutic use]; Lovastatin [therapeutic use]; Nephrotic Syndrome [*drug therapy]; Randomized Controlled Trials as Topic; Simvastatin [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005425.pub2&amp;doi=10.1002/14651858.CD005425.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005425.pub2&amp;doi=10.1002/14651858.CD005425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005425.pub2&amp;doi=10.1002/14651858.CD005425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005425.pub2&amp;doi=10.1002/14651858.CD005425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005425.pub2&amp;doi=10.1002/14651858.CD005425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005425.pub2&amp;doi=10.1002/14651858.CD005425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005425.pub2&amp;doi=10.1002/14651858.CD005425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005425.pub2&amp;doi=10.1002/14651858.CD005425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005425.pub2&amp;doi=10.1002/14651858.CD005425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005425.pub2&amp;doi=10.1002/14651858.CD005425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005425.pub2&amp;doi=10.1002/14651858.CD005425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005425.pub2&amp;doi=10.1002/14651858.CD005425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005425.pub2&amp;doi=10.1002/14651858.CD005425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005425.pub2&amp;doi=10.1002/14651858.CD005425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005425.pub2&amp;doi=10.1002/14651858.CD005425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005425.pub2&amp;doi=10.1002/14651858.CD005425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005425.pub2&amp;doi=10.1002/14651858.CD005425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005425.pub2&amp;doi=10.1002/14651858.CD005425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005425.pub2&amp;doi=10.1002/14651858.CD005425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005425.pub2&amp;doi=10.1002/14651858.CD005425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005425.pub2&amp;doi=10.1002/14651858.CD005425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005425.pub2&amp;doi=10.1002/14651858.CD005425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005425.pub2&amp;doi=10.1002/14651858.CD005425.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="VXKc2U6b";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD005425\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD005425\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005425\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005425\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD005425.pub2",title:"Lipid\\u2010lowering agents for nephrotic syndrome",firstPublishedDate:"Dec 10, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=VXKc2U6b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005425.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005425.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD005425.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD005425.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005425.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD005425.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD005425.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD005425.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD005425.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD005425.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3891 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD005425.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005425.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005425.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005425.pub2/full#CD005425-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005425.pub2/full#CD005425-sec-0095"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005425.pub2/full#CD005425-sec-0022"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005425.pub2/full#CD005425-sec-0029"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005425.pub2/full#CD005425-sec-0030"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005425.pub2/full#CD005425-sec-0052"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005425.pub2/full#CD005425-sec-0089"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005425.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005425.pub2/appendices#CD005425-sec-0100"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005425.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005425.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/table_n/CD005425StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/table_n/CD005425StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005425.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005425.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005425.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005425.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005425.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD005425.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2013 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Lipid‐lowering agents for nephrotic syndrome</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005425.pub2/information#CD005425-cr-0002">Xiangyu Kong</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005425.pub2/information#CD005425-cr-0003">Hao Yuan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005425.pub2/information#CD005425-cr-0004">Junming Fan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005425.pub2/information#CD005425-cr-0005">Zi Li</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005425.pub2/information#CD005425-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Taixiang Wu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005425.pub2/information#CD005425-cr-0007">Lanhui Jiang</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/information/en#CD005425-sec-0104">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 10 December 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD005425.pub2">https://doi.org/10.1002/14651858.CD005425.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD005425-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005425-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005425-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005425-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005425-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD005425-abs-0001" lang="en"> <section id="CD005425-sec-0001"> <h3 class="title" id="CD005425-sec-0001">Background</h3> <p>Nephrotic syndrome is the collective name given to a group of symptoms that include proteinuria, lipiduria, hypoalbuminaemia, oedema, hypercholesterolaemia, elevated triglycerides, and hyperlipidaemia. Hyperlipidaemia is thought to aggravate glomerulosclerosis (hardening of blood vessels in the kidneys) and enhance progression of glomerular disease. Studies have established that reduction in total cholesterol and low density lipoprotein (LDL) cholesterol is associated with reduction in risk of cardiovascular diseases. In 2011, the European Society of Cardiology and European Atherosclerosis Society guidelines for the management of dyslipidaemia recommended use of statins as first‐line agents in the management of nephrotic dyslipidaemia. However, the effectiveness and safety of statins for people with nephrotic syndrome remains uncertain. Furthermore, the efficacy of second‐line lipid‐lowering drugs, such as ezetimibe and nicotinic acid, has not been proven in patients with nephrotic syndrome who are unable to tolerate statin therapy. </p> </section> <section id="CD005425-sec-0002"> <h3 class="title" id="CD005425-sec-0002">Objectives</h3> <p>This review aimed to evaluate the benefits and harms of lipid‐lowering agents in adults and children with nephrotic syndrome. </p> </section> <section id="CD005425-sec-0003"> <h3 class="title" id="CD005425-sec-0003">Search methods</h3> <p>We searched the Cochrane Renal Group's Specialised Register (to 18 March 2013) through contact with the Trials Search Co‐ordinator using search terms relevant to this review. </p> </section> <section id="CD005425-sec-0004"> <h3 class="title" id="CD005425-sec-0004">Selection criteria</h3> <p>All randomised controlled trials (RCTs) and quasi‐RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) looking at participants with nephrotic syndrome that compared any lipid‐lowering agent to placebo, no treatment or other lipid‐lowering agents, given for not less than four weeks, were included. </p> </section> <section id="CD005425-sec-0005"> <h3 class="title" id="CD005425-sec-0005">Data collection and analysis</h3> <p>Two authors independently assessed study eligibility and risk of bias, and extracted data. Statistical analyses were performed using a random effects model. Dichotomous results were expressed as risk ratios (RR) with 95% confidence intervals (CI). For continuous measures mean difference (MD) was used, or the standardised mean difference (SMD) where different scales had been used. </p> </section> <section id="CD005425-sec-0006"> <h3 class="title" id="CD005425-sec-0006">Main results</h3> <p>We included five RCTs enrolling a total of 203 participants. Of these, four studies compared statins with no treatment or placebo, and one compared fibrates with placebo. We found no published studies comparing second‐line agents such as ezetimibe, bile acid sequestrants, and nicotinic acid with placebo or no treatment. Our assessment of the risk of bias found that one study was judged overall to be at low risk of bias and the remaining four were judged to be at high risk of bias. </p> <p>Most outcomes were supported by single study data. One study reported significantly increased high density lipoprotein (HDL) cholesterol among participants in the statin arm compared with the no treatment group (MD 5.40 mg/dL, 95% CI 2.31 to 8.49). Another study reported higher serum albumin in the statin group compared to those who received no treatment (MD 0.60 g/dL, 95% CI 0.14 to 1.06). No serious adverse events, such as rhabdomyolysis, were reported, however some minor events occurred. One study reported no significant difference in the number of participants with elevated liver enzymes (RR 3.00, 95% CI 0.13 to 69.52); three studies reported liver enzymes remained within the normal range (no data provided). Four studies reported creatinine phosphokinase (CPK). One study indicated that CPK values fluctuated in both the simvastatin and placebo groups (no data provided); the remaining three studies reported CPK either stayed within the normal range (one study) or there was no significant difference between the lipid lowering agents and placebo. </p> </section> <section id="CD005425-sec-0007"> <h3 class="title" id="CD005425-sec-0007">Authors' conclusions</h3> <p>None of the included studies reported patient‐centred outcomes including all‐cause mortality, cardiovascular mortality, or non‐fatal myocardial infarction; only single studies reported cholesterol (HDL, LDL and total cholesterol), triglycerides, serum creatinine, blood urea nitrogen, liver enzymes, and protein (serum, urine). High quality RCTs need to be conducted to assess the safety and efficacy of lipid‐lowering drugs for people with nephrotic syndrome. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD005425-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005425-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005425-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005425-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005425-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD005425-abs-0005">Bahasa Malaysia</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD005425-abs-0004" lang="en"> <h3>Lipid‐lowering agents for nephrotic syndrome</h3> <p>Nephrotic syndrome is a relatively rare disease in which the kidneys leak protein into the urine. A common early sign is swelling in the feet and face. Other signs and symptoms of nephrotic syndrome include low levels of protein in the blood, and high levels of fats in the blood, particularly cholesterol and triglycerides. </p> <p>Managing nephrotic syndrome includes therapies to reduce fats (lipids) in the blood. Several types of lipid‐lowering agents including statins, bile acid sequestrants, nicotinic acid and ezetimibe can be used. </p> <p>We looked for evidence from RCTs to establish if lipid‐lowering drugs were beneficial for people with nephrotic syndrome. We found five small studies that investigated four different lipid‐lowering drugs (simvastatin, lovastatin, fluvastatin, gemfibrozil) in 203 participants with nephrotic syndrome. </p> <p>There is currently not enough high quality evidence from published studies to determine if lipid‐lowering agents are helpful in managing dyslipidaemia in people with nephrotic syndrome. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD005425-sec-0095" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD005425-sec-0095"></div> <h3 class="title" id="CD005425-sec-0096">Implications for practice</h3> <section id="CD005425-sec-0096"> <p>The included studies were suboptimal in terms of quality; most results were supported by only one or two studies meaning data could not be pooled for many of our outcomes. No eligible studies considering other categories of lipid‐lowering agents, such as nicotinic acid and bile acid sequestrants were identified. </p> </section> <h3 class="title" id="CD005425-sec-0097">Implications for research</h3> <section id="CD005425-sec-0097"> <p>More robust and relevant studies are needed. The effectiveness and safety of lipid‐lowering agents for participants with nephrotic syndrome need to be investigated. Future researchers should consider focusing on comparisons of lipid‐lowering agents, including nicotinic acid and bile acid sequestrants, with placebo or no treatment. Studies should be designed and undertaken over a long enough time period to measure important outcomes such as all‐cause mortality, cardiovascular mortality and non‐fatal myocardial infarction. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD005425-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD005425-sec-0022"></div> <section id="CD005425-sec-0023"> <h3 class="title" id="CD005425-sec-0023">Description of the condition</h3> <p>Nephrotic syndrome is a relatively rare condition in which the glomeruli of the kidney leak protein from the blood into the urine. It results in hypoproteinaemia, hyperlipidaemia, lipiduria and generalised oedema (<a href="./references#CD005425-bbs2-0042" title="Krishna DasKV . Nephrology ‐ nephrotic syndrome. Textbook of medicine. Fourth. Vol. 2, Jaypee Brothers Medical Publishers Pty. Ltd, 2002:893‐8. ">Krishna Das 2002</a>). Nephrotic syndrome can result from primary glomerular disease or secondary diseases such as systemic lupus erythematosus (<a href="./references#CD005425-bbs2-0033" title="FalkRJ , JennetteC , NachmanPH . Primary glomerular disease ‐ nephrotic syndrome. In: BrennerBM , LevineSA editor(s). Brenner &amp; Rector's the Kidney. 6th Edition. Philadelphia: Saunders, 2001:1266‐83. [ISBN: 0721691749] ">Falk 2001</a>). Primary nephrotic syndrome comprises five histological patterns: minimal‐change glomerulonephritis (GN), membranous GN, mesangial proliferative GN, membranoproliferative GN, and focal segmental glomerulosclerosis (<a href="./references#CD005425-bbs2-0042" title="Krishna DasKV . Nephrology ‐ nephrotic syndrome. Textbook of medicine. Fourth. Vol. 2, Jaypee Brothers Medical Publishers Pty. Ltd, 2002:893‐8. ">Krishna Das 2002</a>). Nephrotic syndrome usually begins insidiously and presents with oedema in the feet and facial puffiness leading to a general, massive oedema. Urinalysis shows massive proteinuria and degrees of haematuria, and biochemistry demonstrates hypoalbuminaemia (&lt; 3 g/dL) and hypercholesterolaemia (usually more than 300 mg/dL) (<a href="./references#CD005425-bbs2-0042" title="Krishna DasKV . Nephrology ‐ nephrotic syndrome. Textbook of medicine. Fourth. Vol. 2, Jaypee Brothers Medical Publishers Pty. Ltd, 2002:893‐8. ">Krishna Das 2002</a>). </p> <section id="CD005425-sec-0024"> <h4 class="title">Characteristics of hyperlipidaemia</h4> <p>Hyperlipidaemia is a common feature of nephrotic syndrome and patients present with elevated total plasma cholesterol, triglyceride and low density lipoprotein (LDL) cholesterol. Very low density lipoprotein (VLDL) cholesterol and high density lipoprotein (HDL) cholesterol levels may be normal. Lipoprotein(a) concentrations may also be elevated (<a href="./references#CD005425-bbs2-0048" title="WheelerDC , BernardDB . Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. American Journal of Kidney Diseases1994;23(3):331‐46. [MEDLINE: 8128933] ">Wheeler 1994</a>). The degree of hyperlipidaemia correlates directly with the severity of the proteinuria, and inversely with the serum albumin (<a href="./references#CD005425-bbs2-0023" title="AppelGB ,  BlumCB ,  ChienS ,  KunisCL ,  AppelAS . The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity. New England Journal of Medicine1985;312(24):1544‐8. [MEDLINE: 3858668] ">Appel 1985</a>). </p> </section> <section id="CD005425-sec-0025"> <h4 class="title">Importance of treatment for hyperlipidaemia</h4> <p>Animal studies have suggested that hyperlipidaemia escalates progression of glomerular injury (<a href="./references#CD005425-bbs2-0026" title="BaggaA , SharmaA , SrivastavaRN . Inefficacy of pefloxacin in steroid‐responsive nephrotic syndrome. Pediatric Nephrology1995;9(6):793‐4. [MEDLINE: 8747133] ">Bagga 1995</a>; <a href="./references#CD005425-bbs2-0035" title='HayslettJP , KrassnerLS , BenschKG , KashgarianM , EpsteinFH . Progression of "lipoid nephrosis" to renal insufficiency. New England Journal of Medicine1969;281(4):181‐7. [MEDLINE: 5790494] '>Hayslett 1969</a>; <a href="./references#CD005425-bbs2-0041" title="KeaneWF . Lipids and the kidney. Kidney International1994;46(3):910‐20. [MEDLINE: 7996813] ">Keane 1994</a>). Accelerated atherosclerosis in the kidney vascular system may contribute to deteriorating kidney function (<a href="./references#CD005425-bbs2-0033" title="FalkRJ , JennetteC , NachmanPH . Primary glomerular disease ‐ nephrotic syndrome. In: BrennerBM , LevineSA editor(s). Brenner &amp; Rector's the Kidney. 6th Edition. Philadelphia: Saunders, 2001:1266‐83. [ISBN: 0721691749] ">Falk 2001</a>). Observational studies in the general population have shown that lipid abnormalities are associated with a reduction in kidney function (<a href="./references#CD005425-bbs2-0027" title="ChanCM . Hyperlipidaemia in chronic kidney disease. Annals of the Academy of Medicine, Singapore2005;34(1):31‐5. [MEDLINE: 15726217] ">Chan 2005</a>). Patients with chronic kidney disease (CKD) are at an increased risk for cardiovascular disease and have higher prevalence of hyperlipidaemia (or dyslipidaemia) than the general population (<a href="./references#CD005425-bbs2-0029" title="CulletonBF ,  LarsonMG ,  WilsonPW ,  EvansJC ,  ParfreyPS ,  LevyD . Cardiovascular disease and mortality in a community‐based cohort with mild renal insufficiency. Kidney International1999;56(6):2214‐9. [MEDLINE: 10594797] ">Culleton 1999</a>; <a href="./references#CD005425-bbs2-0040" title="KasiskeBL . Hyperlipidemia in patients with chronic renal disease. American Journal of Kidney Diseases1998;32(5 Suppl 3):S142‐56. [MEDLINE: 9820472] ">Kasiske 1998</a>). Many studies have elucidated the relationship of coronary artery disease with hypercholesterolaemia (<a href="./references#CD005425-bbs2-0022" title="Anonymous . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet1994;344(8934):1383‐9. [MEDLINE: 7968073] ">4S Group 1994</a>; <a href="./references#CD005425-bbs2-0025" title="Anonymous . Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA1993;269(23):3015‐23. [MEDLINE: 8501844] ">ATP II 1993</a>; <a href="./references#CD005425-bbs2-0034" title="GordonDJ . Cholesterol lowering and total mortality. In: RifkindBM editor(s). Lowering cholesterol in high‐risk individuals and populations. Vol. 24, New York: M Dekker, 1995. [ISBN: 0824794125] ">Gordon 1995</a>; <a href="./references#CD005425-bbs2-0043" title="LawMR , WaldNJ , ThompsonSG . By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?. BMJ1994;308(6925):367‐72. [MEDLINE: 8043072] ">Law 1994</a>; <a href="./references#CD005425-bbs2-0044" title="OrdonezJD , HiattRA , KillebrewEJ , FiremanBH . The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney International1993;44(3):638‐42. [MEDLINE: 8231039] ">Ordonez 1993</a>; <a href="./references#CD005425-bbs2-0045" title="SacksFM , PfefferMA , MoyeLA , RouleauJL , RutherfordJD , ColeTG , et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New England Journal of Medicine1996;335(14):1001‐9. [MEDLINE: 8801446] ">Sacks 1996</a>; <a href="./references#CD005425-bbs2-0046" title="ShepherdJ , CobbeSM , FordI , IslesCG , LorimerAR , MacFarlanePW , et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine1995;333(20):1301‐7. [MEDLINE: 7566020] ">Shepherd 1995</a>). Several clinical trials have established that reduction of total cholesterol or LDL cholesterol in high risk people is associated with a statistically and clinically significant reduction in cardiovascular mortality (<a href="./references#CD005425-bbs2-0031" title="European Association for Cardiovascular Prevention &amp; Rehabilitation, ReinerZ , CatapanoAL , DeBackerG , GrahamI , TaskinenMR , et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal2011;32(1):1769‐818. [MEDLINE: 21712404] ">ESC/EAS 2011</a>). </p> </section> </section> <section id="CD005425-sec-0026"> <h3 class="title" id="CD005425-sec-0026">Description of the intervention</h3> <p>There are many approaches to lowering blood lipids. In addition to drug therapy, lifestyle changes including low‐fat diets and physical activity, as well as functional food and dietary supplements such as fish oil (rich in long chain n‐3 fatty acids), polycosanol, and red yeast rice may be useful. There are several categories of lipid‐lowering agents used to treat patients with hyperlipidaemia. Statins (hydroxymethylglutaryl‐coenzyme A (HMG‐CoA) reductase inhibitors), bile acid sequestrants, cholesterol absorption inhibitors, and nicotinic acid are used for the treatment of hypercholesterolaemia; and fibrates, nicotinic acid, and n‐3 fatty acids are used for the management of hypertriglyceridaemia. Statins, fibrates, nicotinic acid, and cholesteryl ester transfer protein inhibitors are used for the modulation of HDL cholesterol levels. </p> </section> <section id="CD005425-sec-0027"> <h3 class="title" id="CD005425-sec-0027">How the intervention might work</h3> <p>Statins are first‐line lipid lowering agents and are recommended for use in the ESC/EAS guidelines for the management of dyslipidaemia (<a href="./references#CD005425-bbs2-0031" title="European Association for Cardiovascular Prevention &amp; Rehabilitation, ReinerZ , CatapanoAL , DeBackerG , GrahamI , TaskinenMR , et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal2011;32(1):1769‐818. [MEDLINE: 21712404] ">ESC/EAS 2011</a>). Statins reduce cholesterol synthesis in the liver by competitively inhibiting HMG‐CoA reductase activity. The reduction in intracellular cholesterol concentration induces LDL receptor expression on the hepatocyte cell surface, which results in increased extraction of LDL cholesterol from the blood and a decreased concentration of circulating LDL cholesterol and other apoB‐containing lipoproteins including triglyceride‐rich particles. Thus, statins also decrease elevated triglyceride levels and induce a modest increase in HDL cholesterol. Reports have indicated that statins lowered LDL cholesterol levels by 20% to 60% (<a href="./references#CD005425-bbs2-0031" title="European Association for Cardiovascular Prevention &amp; Rehabilitation, ReinerZ , CatapanoAL , DeBackerG , GrahamI , TaskinenMR , et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal2011;32(1):1769‐818. [MEDLINE: 21712404] ">ESC/EAS 2011</a>). </p> <p>Second‐line agents such as bile acid sequestrants or nicotinic acid can be used for patients who develop minor adverse effects from a statin or who are unable to tolerate reduced doses or another statin (<a href="./references#CD005425-bbs2-0038" title="Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. American Journal of Kidney Diseases2003;41(4 Suppl 3):S1‐S91. [MEDLINE: 12671933] ">K/DOQI 2003</a>). </p> <p>Bile acid sequestrants prevent bile acid entry into the blood and thereby remove a large portion of bile acids from enterohepatic circulation. Decreases in bile acid returned to the liver leads to up‐regulation of key enzymes responsible for bile acid synthesis from cholesterol, particularly CYP7A1. The increase in cholesterol catabolism to bile acids results in a compensatory increase in hepatic LDL cholesterol receptor activity, clearing LDL cholesterol from blood circulation and thus reducing LDL cholesterol levels. Studies have shown that bile acid sequestrants can lower total cholesterol levels by up to 30% when used alone, and can further reduce LDL cholesterol by 20% to 40% when used with statins (<a href="./references#CD005425-bbs2-0031" title="European Association for Cardiovascular Prevention &amp; Rehabilitation, ReinerZ , CatapanoAL , DeBackerG , GrahamI , TaskinenMR , et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal2011;32(1):1769‐818. [MEDLINE: 21712404] ">ESC/EAS 2011</a>; <a href="./references#CD005425-bbs2-0047" title="ValeriA , GelfandJ , BlumC , AppelGB . Treatment of hyperlipidaemia of the nephrotic syndrome: A controlled trial. American Journal of Kidney Diseases1986;8(6):388‐96. [MEDLINE: 3544820] ">Valeri 1986</a>). </p> <p>Nicotinic acid has multiple beneficial effects on serum lipids and lipoprotein (<a href="./references#CD005425-bbs2-0039" title="KamannaVS ,  KashyapML . Mechanism of action of niacin. American Journal of Cardiology2008;101(8A):20B‐26B. [PUBMED: 18375237] ">Kamanna 2008</a>). It has been reported that nicotinic acid decreased fatty acid influx to the liver and VLDL cholesterol secretion by the liver. Nicotinic acid has been reported to inhibit diacylglycerol acyltransferase‐2 in the liver resulting in decreased secretion of VLDL particles from the liver, which is also reflected in reductions of HDL and LDL particles. Nicotinic acid raises HDL cholesterol and apolipoprotein A1 (apoA1) primarily by stimulating apoA1 production in the liver. Nicotinic acid is currently used mostly as an extended release form. Nicotinic acid at 2 g daily has been reported to be effective in reducing triglyceride by 20% to 40%, LDL cholesterol by 15% to 18%, and to increase HDL cholesterol by 15% to 35% (<a href="./references#CD005425-bbs2-0039" title="KamannaVS ,  KashyapML . Mechanism of action of niacin. American Journal of Cardiology2008;101(8A):20B‐26B. [PUBMED: 18375237] ">Kamanna 2008</a>). </p> <p>Ezetimibe is the first drug in a new class of cholesterol lowering agents called cholesterol absorption inhibitors. It has a unique mechanism of action compared in that it inhibits the absorption of dietary and biliary cholesterol, decreasing intestinal absorption by 54%. Ezetimibe does not affect absorption of triglycerides or fat‐soluble vitamins (<a href="./references#CD005425-bbs2-0032" title="Zetia (ezetimibe) product information, 2002. Merck/Schering‐Plough Pharmaceuticals. Available from http://www.merck.com/product/usa/pi_circulars/z/zetia/zetia_pi.pdf. ">Ezetimibe PI 2002</a>). Fibrates, including gemfibrozil and clofibrate, can reduce cholesterol by 10% to 30%, lower plasma triglycerides, and may increase HDL levels (<a href="./references#CD005425-bbs2-0033" title="FalkRJ , JennetteC , NachmanPH . Primary glomerular disease ‐ nephrotic syndrome. In: BrennerBM , LevineSA editor(s). Brenner &amp; Rector's the Kidney. 6th Edition. Philadelphia: Saunders, 2001:1266‐83. [ISBN: 0721691749] ">Falk 2001</a>). Fibrates have been reported to be effective in lowering fasting and post‐prandial triglyceride levels and triglyceride‐rich lipoprotein remnant particles. The HDL cholesterol‐raising effects of fibrates are modest (<a href="./references#CD005425-bbs2-0028" title="ChapmanMJ ,  RedfernJS ,  McGovernME ,  GiralP . Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacology &amp; Therapeutics2010;126(3):314‐45. [MEDLINE: 20153365] ">Chapman 2010</a>). </p> </section> <section id="CD005425-sec-0028"> <h3 class="title" id="CD005425-sec-0028">Why it is important to do this review</h3> <p>Although data from post hoc analyses of statin studies provide evidence for the beneficial effects of statin therapy on cardiovascular disease outcomes in patients with stages 2 and 3 CKD; negative results from a study evaluating rosuvastatin in subjects on regular haemodialysis questioned the benefits of statins in these very high risk patients (<a href="./references#CD005425-bbs2-0030" title="De BackerG ,  AmbrosioniE ,  Borch‐JohnsenK ,  BrotonsC ,  CifkovaR ,  DallongevilleJ , et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). European Journal of Cardiovascular Prevention &amp; Rehabilitation2003;10(4):S1‐S10. [MEDLINE: 14555889] ">De Backer 2003</a>). Although statins are generally well tolerated at moderate doses by people with CKD stages 1 and 2, safety issues in those with more advanced CKD (stages 3 to 5) needs further investigation; adverse events are commonly dose‐related and related to increased blood concentration of the compound. For those with dyslipidaemia who are unable to tolerate statins, efficacy of alternative second‐line agents such as ezetimibe and nicotinic acid are unproved. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD005425-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD005425-sec-0029"></div> <p>This review aimed to evaluate the benefits and harms of lipid‐lowering agents in adults and children with nephrotic syndrome. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD005425-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD005425-sec-0030"></div> <section id="CD005425-sec-0031"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD005425-sec-0032"> <h4 class="title">Types of studies</h4> <p>RCTs and quasi‐RCTs (in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods), in any lipid‐lowering agents, doses, routes of administration and duration of treatment in nephrotic syndrome treatment, were included. </p> </section> <section id="CD005425-sec-0033"> <h4 class="title">Types of participants</h4> <p>Adult and children with nephrotic syndrome were included. Diagnosis of nephrotic syndrome in adults was based on proteinuria greater than 3.5 g/24 h and low serum albumin (&lt; 30 g/L). Diagnosis of nephrotic syndrome in children was defined as proteinuria greater than 50 mg/kg/24 h and serum albumin at 2.0 g/dL. We also included studies that investigated participants with nephrotic syndrome but without a definition for nephrotic syndrome. </p> <p>We excluded participants with hepatic disease, muscle disease, diabetes mellitus, systemic lupus erythematosus, hypothyroidism, carcinoma, lymphoma or amyloidosis. We also excluded participants with histories of familial dyslipidaemia. </p> </section> <section id="CD005425-sec-0034"> <h4 class="title">Types of interventions</h4> <p>The following interventions were included.</p> <p> <ol id="CD005425-list-0001"> <li> <p>Any lipid‐lowering agents compared with either no drug or placebo</p> </li> <li> <p>Study duration of not less than four weeks</p> </li> <li> <p>Intervention and control groups that used routine therapy simultaneously.</p> </li> </ol> </p> <p>We excluded studies that administered anti‐proteinuria agents only to intervention group participants. </p> </section> <section id="CD005425-sec-0035"> <h4 class="title">Types of outcome measures</h4> <section id="CD005425-sec-0036"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD005425-list-0002"> <li> <p>All‐cause mortality, cardiovascular mortality, non‐fatal myocardial infarction, stroke</p> </li> <li> <p>Total serum cholesterol, LDL cholesterol, HDL cholesterol, serum triglyceride</p> </li> <li> <p>Blood urea nitrogen (BUN) and serum creatinine (SCr).</p> </li> </ol> </p> <p>We included outcomes which were measured after undergoing lipid‐lowering therapy for at least four weeks. </p> </section> <section id="CD005425-sec-0037"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD005425-list-0003"> <li> <p>Urinary protein excretion (g/24 h)</p> </li> <li> <p>Serum protein</p> </li> <li> <p>Serum apoA and apoB</p> </li> <li> <p>Adverse events: elevated liver enzymes, creatinine phosphokinase (CPK), rhabdomyolysis.</p> </li> </ol> </p> <p>We included outcomes which were measured after undergoing lipid‐lowering therapy for at least four weeks. </p> </section> </section> </section> <section id="CD005425-sec-0038"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD005425-sec-0039"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Renal Group's Specialised Register (18 March 2013) through contact with the Trials' Search Co‐ordinator using search terms relevant to this review. The Cochrane Renal Group’s Specialised Register contains studies identified from the following sources. </p> <p> <ol id="CD005425-list-0004"> <li> <p>Quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Handsearching of kidney‐related journals and the proceedings of major kidney conferences</p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected kidney journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</p> </li> </ol> </p> <p>Studies contained in the Specialised Register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of the Cochrane Renal Group. Details of these strategies as well as a list of handsearched journals, conference proceedings and current awareness alerts are available in the Specialised Register section of information about the <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html" target="_blank">Cochrane Renal Group</a>. </p> <p>See <a href="./appendices#CD005425-sec-0101">Appendix 1</a> for search terms used in strategies for this review. </p> </section> <section id="CD005425-sec-0040"> <h4 class="title">Searching other resources</h4> <p>No additional handsearching was undertaken for this review because the Cochrane Renal Group's Specialised Register includes handsearched records. </p> </section> </section> <section id="CD005425-sec-0041"> <h3 class="title" id="CD005425-sec-0041">Data collection and analysis</h3> <section id="CD005425-sec-0042"> <h4 class="title">Selection of studies</h4> <p>Two authors independently selected studies to be included in the review. Titles, abstracts and keywords of all records retrieved were assessed independently by two authors to identify studies that required further assessment. Full articles were obtained when information in titles, abstracts and keywords suggested that the study investigated lipid‐lowering agents as an intervention; the study was designed prospectively; and included a control group of participants with nephrotic syndrome. Study selection disagreements were resolved by discussion. </p> </section> <section id="CD005425-sec-0043"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was undertaken independently by the same authors using a standardised data extraction form. Where more than one publication of one study existed, reports were grouped together and the publication with the most complete data was used. Disagreements were resolved in consultation with a third review author. </p> </section> <section id="CD005425-sec-0044"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were independently assessed by two authors using the risk of bias assessment tool (<a href="./references#CD005425-bbs2-0037" title="HigginsJ , AltmanD , SterneJ (editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) (see <a href="./appendices#CD005425-sec-0102">Appendix 2</a>). </p> <p> <ul id="CD005425-list-0005"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study?</p> <ul id="CD005425-list-0006"> <li> <p>Participants and personnel (performance bias)</p> </li> <li> <p>Outcome assessors (detection bias)</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at a risk of bias?</p> </li> </ul> </p> <p>We also intended to explore the influence of individual quality criteria in a sensitivity analysis. Each study was evaluated independently by two authors. Iterate agreement was calculated using the Kappa statistic. Disagreements were resolved by consultation and achieved by consensus. </p> </section> <section id="CD005425-sec-0045"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (such as adverse events) results were expressed as risk ratio (RR) with 95% confidence intervals (CI). Continuous outcomes (such as serum total cholesterol, LDL cholesterol, HDL cholesterol, SCr) were assessed using the mean difference (MD) with 95% CI, or the standardised mean difference (SMD) if different scales were used (e.g. proteinuria). In studies where change from baseline data were reported, the change scores were to be used. Where final values were reported, we use final scores only. Where appropriate, final score data and change from baseline were incorporated into meta‐analyses. </p> </section> <section id="CD005425-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>Where required, further information was requested from original authors; however, no responses were received. </p> </section> <section id="CD005425-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to investigate heterogeneity using a Chi² test on N‐1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I² test (<a href="./references#CD005425-bbs2-0036" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [MEDLINE: 12958120] ">Higgins 2003</a>). I² values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity. </p> </section> <section id="CD005425-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess reporting bias by constructing funnel plots to assess for the potential existence of small study bias (<a href="./references#CD005425-bbs2-0037" title="HigginsJ , AltmanD , SterneJ (editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). However, there were insufficient studies to create funnel plots. </p> </section> <section id="CD005425-sec-0049"> <h4 class="title">Data synthesis</h4> <p>Available data were summarised where sufficient clinical and methodological homogeneity was established. Statistical analysis was performed according to the statistical guidelines referenced in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005425-bbs2-0037" title="HigginsJ , AltmanD , SterneJ (editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We planned to pool data using the random‐effects model, and to apply the fixed‐effect model to ensure robustness of the model selection and susceptibility to outliers. </p> </section> <section id="CD005425-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to conduct subgroup analyses to explore the role of potential sources of heterogeneity in modifying estimates of the effects of lipid‐lowering agents in the studies. However, limited data meant that we were unable to conduct subgroup analyses. Our planned subgroup analyses were as follows. </p> <p> <ol id="CD005425-list-0007"> <li> <p>Intervention: lipid‐lowering agents compared with placebo or other current treatment regimen </p> </li> <li> <p>Dose (low, medium, high)</p> </li> <li> <p>Duration</p> </li> <li> <p>Primary or secondary nephrotic syndrome</p> </li> <li> <p>Different histology or aetiology or both of nephrotic syndrome.</p> </li> </ol> </p> </section> <section id="CD005425-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to conduct sensitivity analyses to explore the influence of the following factors on effect size. </p> <p> <ul id="CD005425-list-0008"> <li> <p>Repeating the analysis excluding unpublished studies</p> </li> <li> <p>Repeating the analysis excluding studies which contained participants with significant proteinuria </p> </li> <li> <p>Repeating the analysis taking account of quality of studies and excluding small studies with poor quality </p> </li> </ul> </p> <p>These analyses could not be undertaken because of insufficient study data.</p> <p>Similarly, the robustness of results were also planned to be tested by repeating the analysis using different measures of effects size (e.g. RR and Odds ratio) and different statistical models using fixed‐effect and random‐effects models, again these analyses could not be conducted due to lack of data. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD005425-sec-0052" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD005425-sec-0052"></div> <section id="CD005425-sec-0053"> <h3 class="title">Description of studies</h3> <section id="CD005425-sec-0054"> <h4 class="title">Results of the search</h4> <p>Our search identified 940 potential studies. Of these, 29 were retrieved for further investigation by screening titles and abstracts. After full text assessment, we included five studies (eight reports) (<a href="./references#CD005425-bbs2-0001" title="BuyukcelikM , AnaratA , BayazitAK , NoyanA , OzelA , AnaratR , et al. The effects of gemfibrozil on hyperlipidaemia in children with persistent nephrotic syndrome. Turkish Journal of Pediatrics2002;44(1):40‐4. [MEDLINE: 11858378] ">Buyukcelik 2002</a>; <a href="./references#CD005425-bbs2-0002" title="GheithO , SaadM , SobhM . Nephrotic dyslipidaemia, harvest of treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon (Portugal). 2004:258. GheithO , SobhM , GazarenS , AhmedH , ElBazM . Study the effect of treatment of nephrotic dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):100. GheithOA , SobhMA , MohamedKE , ElBazM , ElHusseiniF , GazarinSS , et al. Impact of treatment of dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron2002;91(4):612‐9. [MEDLINE: 12138263] ">Gheith 2002</a>; <a href="./references#CD005425-bbs2-0003" title="GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidaemia: A preliminary report. European Journal of Internal Medicine2009;20(3):e57–e61. [MEDLINE: 19393480] GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidaemia. Clinical &amp; Experimental Nephrology2008;12(3):189‐94. [MEDLINE: 18363032] ">Gheith 2009</a>; <a href="./references#CD005425-bbs2-0004" title="OlbrichtCJ , WannerC , ThieryJ , BastenA . Simvastatin in nephrotic syndrome. Kidney International ‐ Supplement1999;56(Suppl 71):113‐6. [MEDLINE: 10412752] ">Olbricht 1999</a>; <a href="./references#CD005425-bbs2-0005" title="SharmaM , NandN , AggarwalHK , NandD . Evaluation of effects of lovastatin on hypercholesterolaemia and renal functions in nephrotic syndrome. Indian Academy of Clinical Medicine2004;5(2):143‐6. ">Sharma 2004</a>). One ongoing study was also identified and when published will be assessed for inclusion in a future update (<a href="./references#CD005425-bbs2-0021" title="QuerfeldU . Prospective, multicenter, double‐blind, randomised, cross‐over study to evaluate efficacy and safety of sevelamer in the treatment of dyslipidaemia in children with persisting proteinuria. controlled‐trials.com/ISRCTN06912061 (accessed 9 October 2013). ">ISRCTN06912061</a>). The study selection process is shown in <a href="#CD005425-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD005425-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study selection flow diagram" data-id="CD005425-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study selection flow diagram</p> </div> </div> </div> </section> <section id="CD005425-sec-0055"> <h4 class="title">Included studies</h4> <section id="CD005425-sec-0056"> <h5 class="title">Types of studies</h5> <p>All included studies were RCTs.</p> </section> <section id="CD005425-sec-0057"> <h5 class="title">Types of participants</h5> <p>Although all included studies enrolled participants with nephrotic syndrome, only two provided definitions of nephrotic syndrome. </p> <p> <ul id="CD005425-list-0009"> <li> <p><a href="./references#CD005425-bbs2-0004" title="OlbrichtCJ , WannerC , ThieryJ , BastenA . Simvastatin in nephrotic syndrome. Kidney International ‐ Supplement1999;56(Suppl 71):113‐6. [MEDLINE: 10412752] ">Olbricht 1999</a>: proteinuria &gt; 3 g/24 h in adults </p> </li> <li> <p><a href="./references#CD005425-bbs2-0001" title="BuyukcelikM , AnaratA , BayazitAK , NoyanA , OzelA , AnaratR , et al. The effects of gemfibrozil on hyperlipidaemia in children with persistent nephrotic syndrome. Turkish Journal of Pediatrics2002;44(1):40‐4. [MEDLINE: 11858378] ">Buyukcelik 2002</a>: proteinuria &gt; 40 mg/m²/h in children </p> </li> </ul> </p> <p>It was noted that nephrotic syndrome diagnostic criteria did not match the definition provided in the protocol in <a href="./references#CD005425-bbs2-0004" title="OlbrichtCJ , WannerC , ThieryJ , BastenA . Simvastatin in nephrotic syndrome. Kidney International ‐ Supplement1999;56(Suppl 71):113‐6. [MEDLINE: 10412752] ">Olbricht 1999</a>. </p> <p>Participant numbers among included studies ranged from 12 to 56 (mean = 39). The age of participants ranged from 10 years to 43.8 years. All studies included both males and females. The proportion of females was higher among younger participants (<a href="./references#CD005425-bbs2-0001" title="BuyukcelikM , AnaratA , BayazitAK , NoyanA , OzelA , AnaratR , et al. The effects of gemfibrozil on hyperlipidaemia in children with persistent nephrotic syndrome. Turkish Journal of Pediatrics2002;44(1):40‐4. [MEDLINE: 11858378] ">Buyukcelik 2002</a>; <a href="./references#CD005425-bbs2-0002" title="GheithO , SaadM , SobhM . Nephrotic dyslipidaemia, harvest of treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon (Portugal). 2004:258. GheithO , SobhM , GazarenS , AhmedH , ElBazM . Study the effect of treatment of nephrotic dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):100. GheithOA , SobhMA , MohamedKE , ElBazM , ElHusseiniF , GazarinSS , et al. Impact of treatment of dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron2002;91(4):612‐9. [MEDLINE: 12138263] ">Gheith 2002</a>; <a href="./references#CD005425-bbs2-0003" title="GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidaemia: A preliminary report. European Journal of Internal Medicine2009;20(3):e57–e61. [MEDLINE: 19393480] GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidaemia. Clinical &amp; Experimental Nephrology2008;12(3):189‐94. [MEDLINE: 18363032] ">Gheith 2009</a>), and there were more males among older participants (<a href="./references#CD005425-bbs2-0004" title="OlbrichtCJ , WannerC , ThieryJ , BastenA . Simvastatin in nephrotic syndrome. Kidney International ‐ Supplement1999;56(Suppl 71):113‐6. [MEDLINE: 10412752] ">Olbricht 1999</a>; <a href="./references#CD005425-bbs2-0005" title="SharmaM , NandN , AggarwalHK , NandD . Evaluation of effects of lovastatin on hypercholesterolaemia and renal functions in nephrotic syndrome. Indian Academy of Clinical Medicine2004;5(2):143‐6. ">Sharma 2004</a>). </p> </section> <section id="CD005425-sec-0058"> <h5 class="title">Interventions</h5> <p> <ul id="CD005425-list-0010"> <li> <p>One study compared fibrates (gemfibrozil) with placebo (<a href="./references#CD005425-bbs2-0001" title="BuyukcelikM , AnaratA , BayazitAK , NoyanA , OzelA , AnaratR , et al. The effects of gemfibrozil on hyperlipidaemia in children with persistent nephrotic syndrome. Turkish Journal of Pediatrics2002;44(1):40‐4. [MEDLINE: 11858378] ">Buyukcelik 2002</a>) and four compared statins with placebo or no treatment: fluvastatin (<a href="./references#CD005425-bbs2-0002" title="GheithO , SaadM , SobhM . Nephrotic dyslipidaemia, harvest of treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon (Portugal). 2004:258. GheithO , SobhM , GazarenS , AhmedH , ElBazM . Study the effect of treatment of nephrotic dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):100. GheithOA , SobhMA , MohamedKE , ElBazM , ElHusseiniF , GazarinSS , et al. Impact of treatment of dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron2002;91(4):612‐9. [MEDLINE: 12138263] ">Gheith 2002</a>; <a href="./references#CD005425-bbs2-0003" title="GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidaemia: A preliminary report. European Journal of Internal Medicine2009;20(3):e57–e61. [MEDLINE: 19393480] GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidaemia. Clinical &amp; Experimental Nephrology2008;12(3):189‐94. [MEDLINE: 18363032] ">Gheith 2009</a>); simvastatin (<a href="./references#CD005425-bbs2-0004" title="OlbrichtCJ , WannerC , ThieryJ , BastenA . Simvastatin in nephrotic syndrome. Kidney International ‐ Supplement1999;56(Suppl 71):113‐6. [MEDLINE: 10412752] ">Olbricht 1999</a>); lovastatin (<a href="./references#CD005425-bbs2-0005" title="SharmaM , NandN , AggarwalHK , NandD . Evaluation of effects of lovastatin on hypercholesterolaemia and renal functions in nephrotic syndrome. Indian Academy of Clinical Medicine2004;5(2):143‐6. ">Sharma 2004</a>). All interventions were administered orally. </p> </li> <li> <p>Treatment duration varied from three months to two years; the longest follow‐up duration was two years (<a href="./references#CD005425-bbs2-0004" title="OlbrichtCJ , WannerC , ThieryJ , BastenA . Simvastatin in nephrotic syndrome. Kidney International ‐ Supplement1999;56(Suppl 71):113‐6. [MEDLINE: 10412752] ">Olbricht 1999</a>). </p> </li> <li> <p>None of the included studies compared second‐line agents (e.g. ezetimibe, bile acid sequestrants, nicotinic acid) with placebo or no treatment. </p> </li> <li> <p>Four studies investigated dietary restriction focusing on cholesterol, protein and sodium chloride intake (<a href="./references#CD005425-bbs2-0002" title="GheithO , SaadM , SobhM . Nephrotic dyslipidaemia, harvest of treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon (Portugal). 2004:258. GheithO , SobhM , GazarenS , AhmedH , ElBazM . Study the effect of treatment of nephrotic dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):100. GheithOA , SobhMA , MohamedKE , ElBazM , ElHusseiniF , GazarinSS , et al. Impact of treatment of dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron2002;91(4):612‐9. [MEDLINE: 12138263] ">Gheith 2002</a>; <a href="./references#CD005425-bbs2-0003" title="GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidaemia: A preliminary report. European Journal of Internal Medicine2009;20(3):e57–e61. [MEDLINE: 19393480] GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidaemia. Clinical &amp; Experimental Nephrology2008;12(3):189‐94. [MEDLINE: 18363032] ">Gheith 2009</a>; <a href="./references#CD005425-bbs2-0004" title="OlbrichtCJ , WannerC , ThieryJ , BastenA . Simvastatin in nephrotic syndrome. Kidney International ‐ Supplement1999;56(Suppl 71):113‐6. [MEDLINE: 10412752] ">Olbricht 1999</a>; <a href="./references#CD005425-bbs2-0005" title="SharmaM , NandN , AggarwalHK , NandD . Evaluation of effects of lovastatin on hypercholesterolaemia and renal functions in nephrotic syndrome. Indian Academy of Clinical Medicine2004;5(2):143‐6. ">Sharma 2004</a>). </p> </li> <li> <p>Supportive treatments, including angiotensin‐converting enzyme inhibitors (ACEi), were administered to participants in all included studies. </p> </li> </ul> </p> </section> <section id="CD005425-sec-0059"> <h5 class="title">Outcomes</h5> <section id="CD005425-sec-0060"> <h6 class="title">Primary outcomes</h6> <p> <ul id="CD005425-list-0011"> <li> <p>None of the included studies reported all‐cause mortality, cardiovascular mortality, non‐fatal myocardial infarction, or stroke. </p> </li> <li> <p>All studies reported total cholesterol (<a href="./references#CD005425-bbs2-0001" title="BuyukcelikM , AnaratA , BayazitAK , NoyanA , OzelA , AnaratR , et al. The effects of gemfibrozil on hyperlipidaemia in children with persistent nephrotic syndrome. Turkish Journal of Pediatrics2002;44(1):40‐4. [MEDLINE: 11858378] ">Buyukcelik 2002</a>; <a href="./references#CD005425-bbs2-0002" title="GheithO , SaadM , SobhM . Nephrotic dyslipidaemia, harvest of treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon (Portugal). 2004:258. GheithO , SobhM , GazarenS , AhmedH , ElBazM . Study the effect of treatment of nephrotic dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):100. GheithOA , SobhMA , MohamedKE , ElBazM , ElHusseiniF , GazarinSS , et al. Impact of treatment of dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron2002;91(4):612‐9. [MEDLINE: 12138263] ">Gheith 2002</a>; <a href="./references#CD005425-bbs2-0003" title="GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidaemia: A preliminary report. European Journal of Internal Medicine2009;20(3):e57–e61. [MEDLINE: 19393480] GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidaemia. Clinical &amp; Experimental Nephrology2008;12(3):189‐94. [MEDLINE: 18363032] ">Gheith 2009</a>; <a href="./references#CD005425-bbs2-0004" title="OlbrichtCJ , WannerC , ThieryJ , BastenA . Simvastatin in nephrotic syndrome. Kidney International ‐ Supplement1999;56(Suppl 71):113‐6. [MEDLINE: 10412752] ">Olbricht 1999</a>; <a href="./references#CD005425-bbs2-0005" title="SharmaM , NandN , AggarwalHK , NandD . Evaluation of effects of lovastatin on hypercholesterolaemia and renal functions in nephrotic syndrome. Indian Academy of Clinical Medicine2004;5(2):143‐6. ">Sharma 2004</a>). </p> </li> <li> <p>Four studies (<a href="./references#CD005425-bbs2-0001" title="BuyukcelikM , AnaratA , BayazitAK , NoyanA , OzelA , AnaratR , et al. The effects of gemfibrozil on hyperlipidaemia in children with persistent nephrotic syndrome. Turkish Journal of Pediatrics2002;44(1):40‐4. [MEDLINE: 11858378] ">Buyukcelik 2002</a>; <a href="./references#CD005425-bbs2-0002" title="GheithO , SaadM , SobhM . Nephrotic dyslipidaemia, harvest of treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon (Portugal). 2004:258. GheithO , SobhM , GazarenS , AhmedH , ElBazM . Study the effect of treatment of nephrotic dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):100. GheithOA , SobhMA , MohamedKE , ElBazM , ElHusseiniF , GazarinSS , et al. Impact of treatment of dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron2002;91(4):612‐9. [MEDLINE: 12138263] ">Gheith 2002</a>; <a href="./references#CD005425-bbs2-0004" title="OlbrichtCJ , WannerC , ThieryJ , BastenA . Simvastatin in nephrotic syndrome. Kidney International ‐ Supplement1999;56(Suppl 71):113‐6. [MEDLINE: 10412752] ">Olbricht 1999</a>; <a href="./references#CD005425-bbs2-0005" title="SharmaM , NandN , AggarwalHK , NandD . Evaluation of effects of lovastatin on hypercholesterolaemia and renal functions in nephrotic syndrome. Indian Academy of Clinical Medicine2004;5(2):143‐6. ">Sharma 2004</a>) reported LDL cholesterol, HDL cholesterol, triglycerides, and SCr. </p> </li> </ul> </p> </section> <section id="CD005425-sec-0061"> <h6 class="title">Secondary outcomes</h6> <p> <ul id="CD005425-list-0012"> <li> <p>Two studies reported BUN (<a href="./references#CD005425-bbs2-0001" title="BuyukcelikM , AnaratA , BayazitAK , NoyanA , OzelA , AnaratR , et al. The effects of gemfibrozil on hyperlipidaemia in children with persistent nephrotic syndrome. Turkish Journal of Pediatrics2002;44(1):40‐4. [MEDLINE: 11858378] ">Buyukcelik 2002</a>; <a href="./references#CD005425-bbs2-0005" title="SharmaM , NandN , AggarwalHK , NandD . Evaluation of effects of lovastatin on hypercholesterolaemia and renal functions in nephrotic syndrome. Indian Academy of Clinical Medicine2004;5(2):143‐6. ">Sharma 2004</a>). </p> </li> <li> <p>Four studies reported urinary protein excretion (<a href="./references#CD005425-bbs2-0001" title="BuyukcelikM , AnaratA , BayazitAK , NoyanA , OzelA , AnaratR , et al. The effects of gemfibrozil on hyperlipidaemia in children with persistent nephrotic syndrome. Turkish Journal of Pediatrics2002;44(1):40‐4. [MEDLINE: 11858378] ">Buyukcelik 2002</a>; <a href="./references#CD005425-bbs2-0002" title="GheithO , SaadM , SobhM . Nephrotic dyslipidaemia, harvest of treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon (Portugal). 2004:258. GheithO , SobhM , GazarenS , AhmedH , ElBazM . Study the effect of treatment of nephrotic dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):100. GheithOA , SobhMA , MohamedKE , ElBazM , ElHusseiniF , GazarinSS , et al. Impact of treatment of dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron2002;91(4):612‐9. [MEDLINE: 12138263] ">Gheith 2002</a>; <a href="./references#CD005425-bbs2-0003" title="GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidaemia: A preliminary report. European Journal of Internal Medicine2009;20(3):e57–e61. [MEDLINE: 19393480] GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidaemia. Clinical &amp; Experimental Nephrology2008;12(3):189‐94. [MEDLINE: 18363032] ">Gheith 2009</a>; <a href="./references#CD005425-bbs2-0005" title="SharmaM , NandN , AggarwalHK , NandD . Evaluation of effects of lovastatin on hypercholesterolaemia and renal functions in nephrotic syndrome. Indian Academy of Clinical Medicine2004;5(2):143‐6. ">Sharma 2004</a>). </p> </li> <li> <p>Three studies reported serum protein (total protein or albumin) (<a href="./references#CD005425-bbs2-0001" title="BuyukcelikM , AnaratA , BayazitAK , NoyanA , OzelA , AnaratR , et al. The effects of gemfibrozil on hyperlipidaemia in children with persistent nephrotic syndrome. Turkish Journal of Pediatrics2002;44(1):40‐4. [MEDLINE: 11858378] ">Buyukcelik 2002</a>; <a href="./references#CD005425-bbs2-0002" title="GheithO , SaadM , SobhM . Nephrotic dyslipidaemia, harvest of treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon (Portugal). 2004:258. GheithO , SobhM , GazarenS , AhmedH , ElBazM . Study the effect of treatment of nephrotic dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):100. GheithOA , SobhMA , MohamedKE , ElBazM , ElHusseiniF , GazarinSS , et al. Impact of treatment of dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron2002;91(4):612‐9. [MEDLINE: 12138263] ">Gheith 2002</a>; <a href="./references#CD005425-bbs2-0003" title="GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidaemia: A preliminary report. European Journal of Internal Medicine2009;20(3):e57–e61. [MEDLINE: 19393480] GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidaemia. Clinical &amp; Experimental Nephrology2008;12(3):189‐94. [MEDLINE: 18363032] ">Gheith 2009</a>). </p> </li> <li> <p>Two studies reported serum apoA, apoB (<a href="./references#CD005425-bbs2-0001" title="BuyukcelikM , AnaratA , BayazitAK , NoyanA , OzelA , AnaratR , et al. The effects of gemfibrozil on hyperlipidaemia in children with persistent nephrotic syndrome. Turkish Journal of Pediatrics2002;44(1):40‐4. [MEDLINE: 11858378] ">Buyukcelik 2002</a>; <a href="./references#CD005425-bbs2-0004" title="OlbrichtCJ , WannerC , ThieryJ , BastenA . Simvastatin in nephrotic syndrome. Kidney International ‐ Supplement1999;56(Suppl 71):113‐6. [MEDLINE: 10412752] ">Olbricht 1999</a>). </p> </li> </ul> </p> </section> <section id="CD005425-sec-0062"> <h6 class="title">Adverse events</h6> <p> <ul id="CD005425-list-0013"> <li> <p>CPK was reported in four studies (<a href="./references#CD005425-bbs2-0001" title="BuyukcelikM , AnaratA , BayazitAK , NoyanA , OzelA , AnaratR , et al. The effects of gemfibrozil on hyperlipidaemia in children with persistent nephrotic syndrome. Turkish Journal of Pediatrics2002;44(1):40‐4. [MEDLINE: 11858378] ">Buyukcelik 2002</a>; <a href="./references#CD005425-bbs2-0002" title="GheithO , SaadM , SobhM . Nephrotic dyslipidaemia, harvest of treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon (Portugal). 2004:258. GheithO , SobhM , GazarenS , AhmedH , ElBazM . Study the effect of treatment of nephrotic dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):100. GheithOA , SobhMA , MohamedKE , ElBazM , ElHusseiniF , GazarinSS , et al. Impact of treatment of dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron2002;91(4):612‐9. [MEDLINE: 12138263] ">Gheith 2002</a>; <a href="./references#CD005425-bbs2-0003" title="GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidaemia: A preliminary report. European Journal of Internal Medicine2009;20(3):e57–e61. [MEDLINE: 19393480] GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidaemia. Clinical &amp; Experimental Nephrology2008;12(3):189‐94. [MEDLINE: 18363032] ">Gheith 2009</a>; <a href="./references#CD005425-bbs2-0004" title="OlbrichtCJ , WannerC , ThieryJ , BastenA . Simvastatin in nephrotic syndrome. Kidney International ‐ Supplement1999;56(Suppl 71):113‐6. [MEDLINE: 10412752] ">Olbricht 1999</a>). </p> </li> <li> <p>All studies reported liver enzymes including alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (<a href="./references#CD005425-bbs2-0001" title="BuyukcelikM , AnaratA , BayazitAK , NoyanA , OzelA , AnaratR , et al. The effects of gemfibrozil on hyperlipidaemia in children with persistent nephrotic syndrome. Turkish Journal of Pediatrics2002;44(1):40‐4. [MEDLINE: 11858378] ">Buyukcelik 2002</a>; <a href="./references#CD005425-bbs2-0002" title="GheithO , SaadM , SobhM . Nephrotic dyslipidaemia, harvest of treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon (Portugal). 2004:258. GheithO , SobhM , GazarenS , AhmedH , ElBazM . Study the effect of treatment of nephrotic dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):100. GheithOA , SobhMA , MohamedKE , ElBazM , ElHusseiniF , GazarinSS , et al. Impact of treatment of dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron2002;91(4):612‐9. [MEDLINE: 12138263] ">Gheith 2002</a>; <a href="./references#CD005425-bbs2-0003" title="GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidaemia: A preliminary report. European Journal of Internal Medicine2009;20(3):e57–e61. [MEDLINE: 19393480] GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidaemia. Clinical &amp; Experimental Nephrology2008;12(3):189‐94. [MEDLINE: 18363032] ">Gheith 2009</a>; <a href="./references#CD005425-bbs2-0004" title="OlbrichtCJ , WannerC , ThieryJ , BastenA . Simvastatin in nephrotic syndrome. Kidney International ‐ Supplement1999;56(Suppl 71):113‐6. [MEDLINE: 10412752] ">Olbricht 1999</a>; <a href="./references#CD005425-bbs2-0005" title="SharmaM , NandN , AggarwalHK , NandD . Evaluation of effects of lovastatin on hypercholesterolaemia and renal functions in nephrotic syndrome. Indian Academy of Clinical Medicine2004;5(2):143‐6. ">Sharma 2004</a>). </p> </li> <li> <p>No findings of rhabdomyolysis were reported.</p> </li> </ul> </p> </section> </section> </section> <section id="CD005425-sec-0063"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD005425-sec-0111" title="">Characteristics of excluded studies</a>. </p> <p> <ul id="CD005425-list-0014"> <li> <p>Five studies (seven reports) were not randomised (<a href="./references#CD005425-bbs2-0006" title="Aguilar‐SalinasCA , BarrettPH , KelberJ , DelmezJ , SchonfeldG . Physiologic mechanisms of action of lovastatin in nephrotic syndrome. Journal of Lipid Research1995;36(1):188‐99. [MEDLINE: 7706943] ">Aguilar‐Salinas 1995</a>; <a href="./references#CD005425-bbs2-0010" title="DullaartRP , GansevoortRT ,  SluiterWJ ,  de ZeeuwD ,  de JongPE . The serum lathosterol to cholesterol ratio, an index of cholesterol synthesis, is not elevated in patients with glomerular proteinuria and is not associated with improvement of hyperlipidaemia in response to antiproteinuric treatment. Metabolism1996;45(6):723‐30. [MEDLINE: 8637447] DullaartRP , GansevoortRT ,  SluiterWJ ,  de ZeeuwD ,  de JongPE . The serum lathosterol/cholesterol ratio, an index of cholesterol synthesis, is not elevated in human nephrotic syndrome and is not associated with improvement of hyperlipidaemia in response to antiproteinuric treatment [abstract]. Journal of the American Society of Nephrology1995;6(3):385. ">De Zeeuw 1995</a>; <a href="./references#CD005425-bbs2-0014" title="KalievRR , SydykovaAT , MirrakhimovEM . Effect of lovastatin, exogenous hypobaric hypoxia and its combination on hyperlipidaemia in patients with nephrotic glomerulo‐nephritis [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna (Austria). 2001:151. ">Kaliev 2001</a>; <a href="./references#CD005425-bbs2-0017" title="ReshM , MahmoodiBK , NavisGJ , VeegerNJ , LijferingWM . Statin use in patients with nephrotic syndrome is associated with a lower risk of venous thromboembolism. Thrombosis Research2011;127(5):395‐9. [MEDLINE: 21277007] ">Resh 2011</a>; <a href="./references#CD005425-bbs2-0020" title="TotoRD , GrundySM , VegaGL . Pravastatin treatment of very low density, intermediate density and low density lipoproteins in hypercholesterolaemia and combined hyperlipidaemia secondary to the nephrotic syndrome. American Journal of Nephrology2000;20(1):12‐7. [MEDLINE: 10644862] TotoRD , VeaGL , GrundySM . Pravastatin improves hypercholesterolemia of the nephrotic syndrome by enhancing clearance of apolipoprotein B [abstract]. Journal of the American Society of Nephrology1992;3(3):321. ">Toto 2000</a>) </p> </li> <li> <p>Eight studies included populations that did not match our inclusion criteria (<a href="./references#CD005425-bbs2-0008" title="CruzadoJM , PovedaR , IbernonM , DíazM , FulladosaX , CarreraM , et al. Low‐dose sirolimus combined with angiotensin‐converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy. Nephrology Dialysis Transplantation2011;26(11):3596‐602. [MEDLINE: 21393611] ">Cruzado 2011</a>; <a href="./references#CD005425-bbs2-0011" title="García‐de‐la‐PuenteS ,  Arredondo‐GarcíaJL ,  Gutierrez‐CastrellonP ,  Bojorquez‐OchoaA ,  MayaER ,  Perez‐MartínezM . Efficacy of simvastatin in children with hyperlipidaemia secondary to kidney disorders. Pediatric Nephrology2009;24(6):1205‐10. [MEDLINE: 19238452] ">Garcia de la Puent 2009</a>; <a href="./references#CD005425-bbs2-0012" title="GolperTA , IllingworthDR , MorrisCD , BennettWM . Lovastatin in the treatment of multifactorial hyperlipidaemia associated with proteinuria. American Journal of Kidney Diseases1989;13(4):312‐20. [MEDLINE: 2650539] ">Golper 1989</a>; <a href="./references#CD005425-bbs2-0013" title="GroggelGC , CheungAK , Ellis‐BenigniK , WilsonDE . Treatment of nephrotic hyperlipoproteinaemia with gemfibrozil. Kidney International1989;36(2):266‐71. [MEDLINE: 2779095] ">Groggel 1989</a>; <a href="./references#CD005425-bbs2-0015" title="RabelinkAJ , HeneRJ , ErkelensDW , JolesJA , KoomansHA . Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome. Lancet1988;2(8624):1335‐8. [MEDLINE: 2904053] ">Rabelink 1988</a>; <a href="./references#CD005425-bbs2-0016" title="RaynerBL , ByrneMJ , vanZyl SmitR . A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone. Clinical Nephrology1996;46(4):219‐24. [MEDLINE: 8905205] ">Rayner 1996</a>; <a href="./references#CD005425-bbs2-0018" title="SpitalewitzS , PorushJG , CattranD , WrightN . Treatment of hyperlipidaemia in the nephrotic syndrome: the effects of pravastatin therapy. American Journal of Kidney Diseases1993;22(1):143‐50. [MEDLINE: 8322777] ">Spitalewitz 1993</a>; <a href="./references#CD005425-bbs2-0019" title="ThomasME , HarrisKPG , RamaswamyC , HattersleyJM , WheelerDC , VargheseZ , et al. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney International1993;44(5):1124‐9. [MEDLINE: 8264145] ">Thomas 1993</a>) </p> </li> <li> <p>Two studies (five reports) investigated interventions that were not eligible for inclusion (<a href="./references#CD005425-bbs2-0007" title="ChowdhuryMN , RashidHU , RahmanH , JahanSS , AlamMR , IqbalM . Effect of hilsha fish oil on lipid profile in patients with nephrotic syndrome. Bangladesh Renal Journal2001;20(1):14‐9. [EMBASE: 2002291093] ">Chowdhury 2001</a>; <a href="./references#CD005425-bbs2-0009" title="D'AmicoG , GentileMG . Effect of dietary manipulation on the lipid abnormalities and urinary protein loss in nephrotic patients. Mineral &amp; Electrolyte Metabolism1992;18(2‐5):203‐6. [MEDLINE: 1465059] D'AmicoG , GentileMG . Pharmacological and dietary treatment of lipid abnormalities in nephrotic patients. Kidney International ‐ Supplement1991;39(Suppl 31):65‐9. [MEDLINE: 2046273] D'AmicoG , RemuzziG , MaschioG , GentileMG , GottiE , OldrizziL , et al. Effect of dietary proteins and lipids in patients with membranous nephropathy and nephrotic syndrome. Clinical Nephrology1991;35(6):237‐42. [MEDLINE: 1873936] GentileMG , D'AmicoG , RedaelliL , GottiE , PerticucciE , deBiaseV , et al. Dietary treatment of hyperlipidaemia in patients with nephrotic syndrome. [abstract]. 11th International Congress of Nephrology; 1990 Jul 15‐20; Tokyo (Japan). 1990:121A. ">D'Amico 1991</a>). </p> </li> </ul> </p> </section> </section> <section id="CD005425-sec-0064"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD005425-fig-0002">Figure 2</a> and <a href="#CD005425-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD005425-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD005425-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD005425-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD005425-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD005425-sec-0065"> <h4 class="title">Allocation</h4> <p>Allocation concealment was only reported in one study (<a href="./references#CD005425-bbs2-0003" title="GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidaemia: A preliminary report. European Journal of Internal Medicine2009;20(3):e57–e61. [MEDLINE: 19393480] GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidaemia. Clinical &amp; Experimental Nephrology2008;12(3):189‐94. [MEDLINE: 18363032] ">Gheith 2009</a>). </p> </section> <section id="CD005425-sec-0066"> <h4 class="title">Blinding</h4> <p>Double blinding was reported by <a href="./references#CD005425-bbs2-0004" title="OlbrichtCJ , WannerC , ThieryJ , BastenA . Simvastatin in nephrotic syndrome. Kidney International ‐ Supplement1999;56(Suppl 71):113‐6. [MEDLINE: 10412752] ">Olbricht 1999</a>. Although double blinding was stated in <a href="./references#CD005425-bbs2-0002" title="GheithO , SaadM , SobhM . Nephrotic dyslipidaemia, harvest of treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon (Portugal). 2004:258. GheithO , SobhM , GazarenS , AhmedH , ElBazM . Study the effect of treatment of nephrotic dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):100. GheithOA , SobhMA , MohamedKE , ElBazM , ElHusseiniF , GazarinSS , et al. Impact of treatment of dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron2002;91(4):612‐9. [MEDLINE: 12138263] ">Gheith 2002</a>, <a href="./references#CD005425-bbs2-0003" title="GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidaemia: A preliminary report. European Journal of Internal Medicine2009;20(3):e57–e61. [MEDLINE: 19393480] GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidaemia. Clinical &amp; Experimental Nephrology2008;12(3):189‐94. [MEDLINE: 18363032] ">Gheith 2009</a> and <a href="./references#CD005425-bbs2-0005" title="SharmaM , NandN , AggarwalHK , NandD . Evaluation of effects of lovastatin on hypercholesterolaemia and renal functions in nephrotic syndrome. Indian Academy of Clinical Medicine2004;5(2):143‐6. ">Sharma 2004</a>, we were unable to verify if this was undertaken. Blinding was believed to be conducted in <a href="./references#CD005425-bbs2-0001" title="BuyukcelikM , AnaratA , BayazitAK , NoyanA , OzelA , AnaratR , et al. The effects of gemfibrozil on hyperlipidaemia in children with persistent nephrotic syndrome. Turkish Journal of Pediatrics2002;44(1):40‐4. [MEDLINE: 11858378] ">Buyukcelik 2002</a> considering the use of placebo. </p> </section> <section id="CD005425-sec-0067"> <h4 class="title">Incomplete outcome data</h4> <p>All studies reported the course of treatment and follow‐up time. Four studies reported that there were no missing data (<a href="./references#CD005425-bbs2-0001" title="BuyukcelikM , AnaratA , BayazitAK , NoyanA , OzelA , AnaratR , et al. The effects of gemfibrozil on hyperlipidaemia in children with persistent nephrotic syndrome. Turkish Journal of Pediatrics2002;44(1):40‐4. [MEDLINE: 11858378] ">Buyukcelik 2002</a>; <a href="./references#CD005425-bbs2-0002" title="GheithO , SaadM , SobhM . Nephrotic dyslipidaemia, harvest of treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon (Portugal). 2004:258. GheithO , SobhM , GazarenS , AhmedH , ElBazM . Study the effect of treatment of nephrotic dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):100. GheithOA , SobhMA , MohamedKE , ElBazM , ElHusseiniF , GazarinSS , et al. Impact of treatment of dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron2002;91(4):612‐9. [MEDLINE: 12138263] ">Gheith 2002</a>; <a href="./references#CD005425-bbs2-0003" title="GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidaemia: A preliminary report. European Journal of Internal Medicine2009;20(3):e57–e61. [MEDLINE: 19393480] GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidaemia. Clinical &amp; Experimental Nephrology2008;12(3):189‐94. [MEDLINE: 18363032] ">Gheith 2009</a>; <a href="./references#CD005425-bbs2-0005" title="SharmaM , NandN , AggarwalHK , NandD . Evaluation of effects of lovastatin on hypercholesterolaemia and renal functions in nephrotic syndrome. Indian Academy of Clinical Medicine2004;5(2):143‐6. ">Sharma 2004</a>), and one addressed missing data (<a href="./references#CD005425-bbs2-0004" title="OlbrichtCJ , WannerC , ThieryJ , BastenA . Simvastatin in nephrotic syndrome. Kidney International ‐ Supplement1999;56(Suppl 71):113‐6. [MEDLINE: 10412752] ">Olbricht 1999</a>). Intention‐to‐treat analysis was performed in four studies; <a href="./references#CD005425-bbs2-0004" title="OlbrichtCJ , WannerC , ThieryJ , BastenA . Simvastatin in nephrotic syndrome. Kidney International ‐ Supplement1999;56(Suppl 71):113‐6. [MEDLINE: 10412752] ">Olbricht 1999</a> conducted per‐protocol analysis. </p> </section> <section id="CD005425-sec-0068"> <h4 class="title">Selective reporting</h4> <p>All studies were considered to be at high risk of reporting bias; primary outcomes such as all‐cause mortality and stroke were not reported. </p> </section> <section id="CD005425-sec-0069"> <h4 class="title">Other potential sources of bias</h4> <p>Reporting was insufficient in all studies to determine any other potential sources of bias. </p> <section id="CD005425-sec-0070"> <h5 class="title">Compliance assessment</h5> <p>Only <a href="./references#CD005425-bbs2-0001" title="BuyukcelikM , AnaratA , BayazitAK , NoyanA , OzelA , AnaratR , et al. The effects of gemfibrozil on hyperlipidaemia in children with persistent nephrotic syndrome. Turkish Journal of Pediatrics2002;44(1):40‐4. [MEDLINE: 11858378] ">Buyukcelik 2002</a> described methods to monitor compliance. This was done by monthly laboratory tests to determine adherence to the treatment. </p> </section> <section id="CD005425-sec-0071"> <h5 class="title">Baseline characteristics</h5> <p>Similarities in baseline characteristics between groups were reported in four studies (<a href="./references#CD005425-bbs2-0002" title="GheithO , SaadM , SobhM . Nephrotic dyslipidaemia, harvest of treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon (Portugal). 2004:258. GheithO , SobhM , GazarenS , AhmedH , ElBazM . Study the effect of treatment of nephrotic dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):100. GheithOA , SobhMA , MohamedKE , ElBazM , ElHusseiniF , GazarinSS , et al. Impact of treatment of dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron2002;91(4):612‐9. [MEDLINE: 12138263] ">Gheith 2002</a>; <a href="./references#CD005425-bbs2-0003" title="GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidaemia: A preliminary report. European Journal of Internal Medicine2009;20(3):e57–e61. [MEDLINE: 19393480] GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidaemia. Clinical &amp; Experimental Nephrology2008;12(3):189‐94. [MEDLINE: 18363032] ">Gheith 2009</a>; <a href="./references#CD005425-bbs2-0004" title="OlbrichtCJ , WannerC , ThieryJ , BastenA . Simvastatin in nephrotic syndrome. Kidney International ‐ Supplement1999;56(Suppl 71):113‐6. [MEDLINE: 10412752] ">Olbricht 1999</a>; <a href="./references#CD005425-bbs2-0005" title="SharmaM , NandN , AggarwalHK , NandD . Evaluation of effects of lovastatin on hypercholesterolaemia and renal functions in nephrotic syndrome. Indian Academy of Clinical Medicine2004;5(2):143‐6. ">Sharma 2004</a>). </p> </section> <section id="CD005425-sec-0072"> <h5 class="title">Cointerventions</h5> <p>Supportive treatments, including ACEi, were reported by four studies (<a href="./references#CD005425-bbs2-0001" title="BuyukcelikM , AnaratA , BayazitAK , NoyanA , OzelA , AnaratR , et al. The effects of gemfibrozil on hyperlipidaemia in children with persistent nephrotic syndrome. Turkish Journal of Pediatrics2002;44(1):40‐4. [MEDLINE: 11858378] ">Buyukcelik 2002</a>; <a href="./references#CD005425-bbs2-0002" title="GheithO , SaadM , SobhM . Nephrotic dyslipidaemia, harvest of treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon (Portugal). 2004:258. GheithO , SobhM , GazarenS , AhmedH , ElBazM . Study the effect of treatment of nephrotic dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):100. GheithOA , SobhMA , MohamedKE , ElBazM , ElHusseiniF , GazarinSS , et al. Impact of treatment of dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron2002;91(4):612‐9. [MEDLINE: 12138263] ">Gheith 2002</a>; <a href="./references#CD005425-bbs2-0003" title="GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidaemia: A preliminary report. European Journal of Internal Medicine2009;20(3):e57–e61. [MEDLINE: 19393480] GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidaemia. Clinical &amp; Experimental Nephrology2008;12(3):189‐94. [MEDLINE: 18363032] ">Gheith 2009</a>; <a href="./references#CD005425-bbs2-0004" title="OlbrichtCJ , WannerC , ThieryJ , BastenA . Simvastatin in nephrotic syndrome. Kidney International ‐ Supplement1999;56(Suppl 71):113‐6. [MEDLINE: 10412752] ">Olbricht 1999</a>). Three studies reported that supportive treatment was the same in both intervention and control groups (<a href="./references#CD005425-bbs2-0002" title="GheithO , SaadM , SobhM . Nephrotic dyslipidaemia, harvest of treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon (Portugal). 2004:258. GheithO , SobhM , GazarenS , AhmedH , ElBazM . Study the effect of treatment of nephrotic dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):100. GheithOA , SobhMA , MohamedKE , ElBazM , ElHusseiniF , GazarinSS , et al. Impact of treatment of dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron2002;91(4):612‐9. [MEDLINE: 12138263] ">Gheith 2002</a>; <a href="./references#CD005425-bbs2-0003" title="GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidaemia: A preliminary report. European Journal of Internal Medicine2009;20(3):e57–e61. [MEDLINE: 19393480] GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidaemia. Clinical &amp; Experimental Nephrology2008;12(3):189‐94. [MEDLINE: 18363032] ">Gheith 2009</a>; <a href="./references#CD005425-bbs2-0004" title="OlbrichtCJ , WannerC , ThieryJ , BastenA . Simvastatin in nephrotic syndrome. Kidney International ‐ Supplement1999;56(Suppl 71):113‐6. [MEDLINE: 10412752] ">Olbricht 1999</a>). </p> <p>Dietary restriction, including cholesterol, protein and sodium chloride intake, was performed in four studies (<a href="./references#CD005425-bbs2-0002" title="GheithO , SaadM , SobhM . Nephrotic dyslipidaemia, harvest of treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon (Portugal). 2004:258. GheithO , SobhM , GazarenS , AhmedH , ElBazM . Study the effect of treatment of nephrotic dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):100. GheithOA , SobhMA , MohamedKE , ElBazM , ElHusseiniF , GazarinSS , et al. Impact of treatment of dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron2002;91(4):612‐9. [MEDLINE: 12138263] ">Gheith 2002</a>; <a href="./references#CD005425-bbs2-0003" title="GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidaemia: A preliminary report. European Journal of Internal Medicine2009;20(3):e57–e61. [MEDLINE: 19393480] GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidaemia. Clinical &amp; Experimental Nephrology2008;12(3):189‐94. [MEDLINE: 18363032] ">Gheith 2009</a>; <a href="./references#CD005425-bbs2-0004" title="OlbrichtCJ , WannerC , ThieryJ , BastenA . Simvastatin in nephrotic syndrome. Kidney International ‐ Supplement1999;56(Suppl 71):113‐6. [MEDLINE: 10412752] ">Olbricht 1999</a>; <a href="./references#CD005425-bbs2-0005" title="SharmaM , NandN , AggarwalHK , NandD . Evaluation of effects of lovastatin on hypercholesterolaemia and renal functions in nephrotic syndrome. Indian Academy of Clinical Medicine2004;5(2):143‐6. ">Sharma 2004</a>); participants in <a href="./references#CD005425-bbs2-0001" title="BuyukcelikM , AnaratA , BayazitAK , NoyanA , OzelA , AnaratR , et al. The effects of gemfibrozil on hyperlipidaemia in children with persistent nephrotic syndrome. Turkish Journal of Pediatrics2002;44(1):40‐4. [MEDLINE: 11858378] ">Buyukcelik 2002</a> maintained their usual diets. </p> </section> </section> </section> <section id="CD005425-sec-0073"> <h3 class="title" id="CD005425-sec-0073">Effects of interventions</h3> <section id="CD005425-sec-0074"> <h4 class="title">Primary outcomes</h4> <p>All‐cause mortality, cardiovascular mortality, non‐fatal myocardial infarction, and stroke were not reported in any of the included studies. </p> <section id="CD005425-sec-0075"> <h5 class="title">Cholesterol and triglycerides</h5> <section id="CD005425-sec-0076"> <h6 class="title">Statins versus placebo or no treatment</h6> <p><a href="./references#CD005425-bbs2-0005" title="SharmaM , NandN , AggarwalHK , NandD . Evaluation of effects of lovastatin on hypercholesterolaemia and renal functions in nephrotic syndrome. Indian Academy of Clinical Medicine2004;5(2):143‐6. ">Sharma 2004</a> reported a significant increase in HDL cholesterol in the statin group after treatment compared to no treatment (<a href="./references#CD005425-fig-0006" title="">Analysis 1.3</a>.1 (1 study, 40 participants): MD 5.40 mg/dL, 95% CI 2.31 to 8.49). </p> <p>There were no significant differences between statins and placebo or no treatment for any of the other serum lipid outcomes. </p> <p> <ul id="CD005425-list-0015"> <li> <p>Total serum cholesterol after three months of treatment (<a href="./references#CD005425-fig-0004" title="">Analysis 1.1</a>.1 (2 studies, 92 participants): MD ‐53.04 mg/dL, 95% CI ‐159.53 to 53.45), six months (<a href="./references#CD005425-fig-0004" title="">Analysis 1.1</a>.2 (1 study, 52 participants): MD ‐45.00 mg/dL, 95% CI ‐144.57 to 54.57), or one year (<a href="./references#CD005425-fig-0004" title="">Analysis 1.1</a>.3 (1 study, 52 participants): MD ‐46.00 mg/dL, 95% CI ‐144.26 to 52.26) </p> </li> <li> <p>LDL cholesterol after three months of treatment (<a href="./references#CD005425-fig-0005" title="">Analysis 1.2</a>.1 (1 study, 40 participants): MD ‐5.05 mg/dL, 95% CI ‐68.31 to 58.21) </p> </li> <li> <p>Triglycerides after three months of treatment (<a href="./references#CD005425-fig-0007" title="">Analysis 1.4</a>.1 (1 study, 40 participants): MD ‐38.85 mg/dL, 95% CI ‐110.2 to 32.58). </p> </li> </ul> </p> <p>There was potential heterogeneity in the results after three months of treatment (I² = 74%, P = 0.05). Two studies described reduction in total cholesterol, LDL cholesterol, triglycerides and an increase in HDL cholesterol in the statins group after treatment (<a href="./references#CD005425-bbs2-0002" title="GheithO , SaadM , SobhM . Nephrotic dyslipidaemia, harvest of treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon (Portugal). 2004:258. GheithO , SobhM , GazarenS , AhmedH , ElBazM . Study the effect of treatment of nephrotic dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):100. GheithOA , SobhMA , MohamedKE , ElBazM , ElHusseiniF , GazarinSS , et al. Impact of treatment of dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron2002;91(4):612‐9. [MEDLINE: 12138263] ">Gheith 2002</a>; <a href="./references#CD005425-bbs2-0004" title="OlbrichtCJ , WannerC , ThieryJ , BastenA . Simvastatin in nephrotic syndrome. Kidney International ‐ Supplement1999;56(Suppl 71):113‐6. [MEDLINE: 10412752] ">Olbricht 1999</a>). <a href="./references#CD005425-bbs2-0002" title="GheithO , SaadM , SobhM . Nephrotic dyslipidaemia, harvest of treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon (Portugal). 2004:258. GheithO , SobhM , GazarenS , AhmedH , ElBazM . Study the effect of treatment of nephrotic dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):100. GheithOA , SobhMA , MohamedKE , ElBazM , ElHusseiniF , GazarinSS , et al. Impact of treatment of dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron2002;91(4):612‐9. [MEDLINE: 12138263] ">Gheith 2002</a> reported mean changes for outcomes without SD; <a href="./references#CD005425-bbs2-0004" title="OlbrichtCJ , WannerC , ThieryJ , BastenA . Simvastatin in nephrotic syndrome. Kidney International ‐ Supplement1999;56(Suppl 71):113‐6. [MEDLINE: 10412752] ">Olbricht 1999</a> reported outcome medians only. </p> </section> <section id="CD005425-sec-0077"> <h6 class="title">Fibrates versus placebo</h6> <p><a href="./references#CD005425-bbs2-0001" title="BuyukcelikM , AnaratA , BayazitAK , NoyanA , OzelA , AnaratR , et al. The effects of gemfibrozil on hyperlipidaemia in children with persistent nephrotic syndrome. Turkish Journal of Pediatrics2002;44(1):40‐4. [MEDLINE: 11858378] ">Buyukcelik 2002</a> reported no significant difference between fibrates and placebo in total serum cholesterol (<a href="./references#CD005425-fig-0004" title="">Analysis 1.1</a>.4 (1 study, 12 participants): MD 42.00 mg/dL, 95% CI ‐33.63 to 117.63), LDL cholesterol (<a href="./references#CD005425-fig-0005" title="">Analysis 1.2</a>.2 (1 study, 12 participants): MD 19.00 mg/dL, 95% CI ‐47.96 to 85.96), HDL cholesterol (<a href="./references#CD005425-fig-0006" title="">Analysis 1.3</a>.2 (1 study, 12 participants): MD 12.10 mg/dL, 95% CI ‐1.83 to 26.03); or triglycerides (<a href="./references#CD005425-fig-0007" title="">Analysis 1.4</a>.2 (1 study, 12 participants): MD ‐231.30 mg/dL, 95% CI ‐465.60 to 3.00). </p> </section> </section> <section id="CD005425-sec-0078"> <h5 class="title">Serum creatinine, blood urea nitrogen</h5> <section id="CD005425-sec-0079"> <h6 class="title">Statins versus placebo or no treatment</h6> <p><a href="./references#CD005425-bbs2-0005" title="SharmaM , NandN , AggarwalHK , NandD . Evaluation of effects of lovastatin on hypercholesterolaemia and renal functions in nephrotic syndrome. Indian Academy of Clinical Medicine2004;5(2):143‐6. ">Sharma 2004</a> reported no significant difference in SCr between the statin and no treatment groups at three months (<a href="./references#CD005425-fig-0008" title="">Analysis 1.5</a>.1 (1 study, 40 participants): MD ‐0.02 mg/dL, 95% CI ‐0.11 to 0.07) and <a href="./references#CD005425-bbs2-0003" title="GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidaemia: A preliminary report. European Journal of Internal Medicine2009;20(3):e57–e61. [MEDLINE: 19393480] GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidaemia. Clinical &amp; Experimental Nephrology2008;12(3):189‐94. [MEDLINE: 18363032] ">Gheith 2009</a> reported no significant difference in SCr at six months (<a href="./references#CD005425-fig-0008" title="">Analysis 1.5</a>.2 (1 study, 52 participants): MD 0.13 mg/dL, 95% CI ‐0.25 to 0.51) or one year (<a href="./references#CD005425-fig-0008" title="">Analysis 1.5</a>.3 (1 study, 52 participants): MD 0.21 mg/dL, 95% CI ‐0.14 to 0.56). </p> <p><a href="./references#CD005425-bbs2-0005" title="SharmaM , NandN , AggarwalHK , NandD . Evaluation of effects of lovastatin on hypercholesterolaemia and renal functions in nephrotic syndrome. Indian Academy of Clinical Medicine2004;5(2):143‐6. ">Sharma 2004</a> reported no significant difference in BUN between the statin and no treatment groups (<a href="./references#CD005425-fig-0009" title="">Analysis 1.6</a> (1 study, 40 participants): MD ‐2.50 mg/dL, 95% CI ‐5.82 to 0.82). </p> <p><a href="./references#CD005425-bbs2-0004" title="OlbrichtCJ , WannerC , ThieryJ , BastenA . Simvastatin in nephrotic syndrome. Kidney International ‐ Supplement1999;56(Suppl 71):113‐6. [MEDLINE: 10412752] ">Olbricht 1999</a> described an elevation in SCr during simvastatin treatment without providing exact values. </p> </section> <section id="CD005425-sec-0080"> <h6 class="title">Fibrates versus placebo</h6> <p><a href="./references#CD005425-bbs2-0001" title="BuyukcelikM , AnaratA , BayazitAK , NoyanA , OzelA , AnaratR , et al. The effects of gemfibrozil on hyperlipidaemia in children with persistent nephrotic syndrome. Turkish Journal of Pediatrics2002;44(1):40‐4. [MEDLINE: 11858378] ">Buyukcelik 2002</a> reported no significant difference between the fibrate and placebo groups for SCr (<a href="./references#CD005425-fig-0008" title="">Analysis 1.5</a> (1 study, 12 participants): MD ‐0.40 mg/dL, 95% CI ‐0.97 to 0.17) or BUN (<a href="./references#CD005425-fig-0009" title="">Analysis 1.6</a> (1 study, 12 participants): MD ‐8.50 mg/dL, 95% CI ‐23.47 to 6.47). </p> </section> </section> </section> <section id="CD005425-sec-0081"> <h4 class="title">Secondary outcomes</h4> <section id="CD005425-sec-0082"> <h5 class="title">Statins versus placebo or no treatment</h5> <p><a href="./references#CD005425-bbs2-0005" title="SharmaM , NandN , AggarwalHK , NandD . Evaluation of effects of lovastatin on hypercholesterolaemia and renal functions in nephrotic syndrome. Indian Academy of Clinical Medicine2004;5(2):143‐6. ">Sharma 2004</a> reported no significant difference in urinary protein excretion between the statin and no treatment group (<a href="./references#CD005425-fig-0010" title="">Analysis 1.7</a>.1 (1 study, 40 participants): SMD ‐0.08, 95% CI ‐0.7 to 0.54). </p> <p><a href="./references#CD005425-bbs2-0003" title="GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidaemia: A preliminary report. European Journal of Internal Medicine2009;20(3):e57–e61. [MEDLINE: 19393480] GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidaemia. Clinical &amp; Experimental Nephrology2008;12(3):189‐94. [MEDLINE: 18363032] ">Gheith 2009</a> reported no significant difference in serum albumin between the statin and no treatment groups at six months (<a href="./references#CD005425-fig-0011" title="">Analysis 1.8</a>.1 (1 study, 52 participants): MD 0.40 g/dL, 95% CI ‐0.06 to 0.86). However, there was a significant increase in serum albumin in the statin group compared with the no treatment group at one year (<a href="./references#CD005425-fig-0011" title="">Analysis 1.8</a>.2 (1 study, 52 participants): MD 0.60 g/dL, 95% CI 0.14 to 1.06). </p> <p><a href="./references#CD005425-bbs2-0004" title="OlbrichtCJ , WannerC , ThieryJ , BastenA . Simvastatin in nephrotic syndrome. Kidney International ‐ Supplement1999;56(Suppl 71):113‐6. [MEDLINE: 10412752] ">Olbricht 1999</a> reported no change in apoA in either the statin or placebo groups, but did not report values. </p> </section> <section id="CD005425-sec-0083"> <h5 class="title">Fibrates versus placebo</h5> <p><a href="./references#CD005425-bbs2-0001" title="BuyukcelikM , AnaratA , BayazitAK , NoyanA , OzelA , AnaratR , et al. The effects of gemfibrozil on hyperlipidaemia in children with persistent nephrotic syndrome. Turkish Journal of Pediatrics2002;44(1):40‐4. [MEDLINE: 11858378] ">Buyukcelik 2002</a> reported no significant difference between the fibrate and placebo groups for proteinuria (<a href="./references#CD005425-fig-0010" title="">Analysis 1.7</a>.2 (1 study, 12 participants): SMD ‐0.16, 95% CI ‐1.31 to 0.99); serum albumin (<a href="./references#CD005425-fig-0011" title="">Analysis 1.8</a>.3 (1 study, 12 participants): MD ‐0.50 g/dL, 95% CI ‐1.12 to 0.12); total serum protein (<a href="./references#CD005425-fig-0012" title="">Analysis 1.9</a> (1 study, 12 participants): MD ‐0.80 g/dL, 95% CI ‐2.18 to 0.58); apoA (<a href="./references#CD005425-fig-0013" title="">Analysis 1.10</a> (1 study, 12 participants): MD 9.50 mg/dL, 95% CI ‐21.28 to 40.28); or apoB (<a href="./references#CD005425-fig-0014" title="">Analysis 1.11</a> (1 study, 12 participants): MD 36.40 mg/dL, 95% CI ‐33.60 to 106.40). </p> </section> <section id="CD005425-sec-0084"> <h5 class="title">Subgroup analyses</h5> <p>There were insufficient data to enable pooling for subgroup analyses for any outcome. Analyses were based on single study data. </p> </section> </section> <section id="CD005425-sec-0085"> <h4 class="title">Adverse events</h4> <section id="CD005425-sec-0086"> <h5 class="title">Statins versus placebo or no treatment</h5> <p><a href="./references#CD005425-bbs2-0005" title="SharmaM , NandN , AggarwalHK , NandD . Evaluation of effects of lovastatin on hypercholesterolaemia and renal functions in nephrotic syndrome. Indian Academy of Clinical Medicine2004;5(2):143‐6. ">Sharma 2004</a> reported no significant difference in elevated liver enzymes between the statin and no treatment group (<a href="./references#CD005425-fig-0015" title="">Analysis 1.12</a> (1 study, 40 participants), RR 3.00, 95% CI 0.13 to 69.52). Three studies reported liver enzymes remained in the normal range throughout the study without reporting the data (<a href="./references#CD005425-bbs2-0002" title="GheithO , SaadM , SobhM . Nephrotic dyslipidaemia, harvest of treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon (Portugal). 2004:258. GheithO , SobhM , GazarenS , AhmedH , ElBazM . Study the effect of treatment of nephrotic dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):100. GheithOA , SobhMA , MohamedKE , ElBazM , ElHusseiniF , GazarinSS , et al. Impact of treatment of dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron2002;91(4):612‐9. [MEDLINE: 12138263] ">Gheith 2002</a>; <a href="./references#CD005425-bbs2-0003" title="GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidaemia: A preliminary report. European Journal of Internal Medicine2009;20(3):e57–e61. [MEDLINE: 19393480] GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidaemia. Clinical &amp; Experimental Nephrology2008;12(3):189‐94. [MEDLINE: 18363032] ">Gheith 2009</a>; <a href="./references#CD005425-bbs2-0004" title="OlbrichtCJ , WannerC , ThieryJ , BastenA . Simvastatin in nephrotic syndrome. Kidney International ‐ Supplement1999;56(Suppl 71):113‐6. [MEDLINE: 10412752] ">Olbricht 1999</a>). </p> <p><a href="./references#CD005425-bbs2-0004" title="OlbrichtCJ , WannerC , ThieryJ , BastenA . Simvastatin in nephrotic syndrome. Kidney International ‐ Supplement1999;56(Suppl 71):113‐6. [MEDLINE: 10412752] ">Olbricht 1999</a> reported CPK values fluctuated in both the simvastatin and placebo groups, but enzyme elevations were not accompanied by clinical symptoms. <a href="./references#CD005425-bbs2-0002" title="GheithO , SaadM , SobhM . Nephrotic dyslipidaemia, harvest of treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon (Portugal). 2004:258. GheithO , SobhM , GazarenS , AhmedH , ElBazM . Study the effect of treatment of nephrotic dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):100. GheithOA , SobhMA , MohamedKE , ElBazM , ElHusseiniF , GazarinSS , et al. Impact of treatment of dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron2002;91(4):612‐9. [MEDLINE: 12138263] ">Gheith 2002</a> reported that CPK was in the normal range in both study arms; <a href="./references#CD005425-bbs2-0003" title="GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidaemia: A preliminary report. European Journal of Internal Medicine2009;20(3):e57–e61. [MEDLINE: 19393480] GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidaemia. Clinical &amp; Experimental Nephrology2008;12(3):189‐94. [MEDLINE: 18363032] ">Gheith 2009</a> found no significant difference in CPK over the course of the study. </p> <p>There were no reports of rhabdomyolysis however <a href="./references#CD005425-bbs2-0005" title="SharmaM , NandN , AggarwalHK , NandD . Evaluation of effects of lovastatin on hypercholesterolaemia and renal functions in nephrotic syndrome. Indian Academy of Clinical Medicine2004;5(2):143‐6. ">Sharma 2004</a> reported two cases of myalgia in the lovastatin group. </p> </section> <section id="CD005425-sec-0087"> <h5 class="title">Fibrates versus placebo</h5> <p><a href="./references#CD005425-bbs2-0001" title="BuyukcelikM , AnaratA , BayazitAK , NoyanA , OzelA , AnaratR , et al. The effects of gemfibrozil on hyperlipidaemia in children with persistent nephrotic syndrome. Turkish Journal of Pediatrics2002;44(1):40‐4. [MEDLINE: 11858378] ">Buyukcelik 2002</a> reported no significant difference in ALT (<a href="./references#CD005425-fig-0016" title="">Analysis 1.13</a> (1 study, 12 participants): MD ‐0.80 U/L, 95% CI ‐4.05 to 2.45), AST (<a href="./references#CD005425-fig-0017" title="">Analysis 1.14</a> (1 study, 12 participants): MD 1.30 U/L, 95% CI ‐11.34 to 13.94), or CPK (<a href="./references#CD005425-fig-0018" title="">Analysis 1.15</a> (1 study, 12 participants): MD 9.00 U/L, 95% CI ‐36.72 to 54.72) levels before and after treatment in fibrates group. </p> </section> <section id="CD005425-sec-0088"> <h5 class="title">Subgroup analyses</h5> <p>There were insufficient data to conduct subgroup analysis for any outcome. The analyses were in the main based on single study data. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD005425-sec-0089" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD005425-sec-0089"></div> <section id="CD005425-sec-0090"> <h3 class="title" id="CD005425-sec-0090">Summary of main results</h3> <p>We were only able to identify five small studies enrolling 203 patients, and therefore were unable to perform meta‐analyses for the majority of our planned outcomes. One study (40 participants) reported a significant increase in HDL cholesterol in those treated with statins compared to no treatment (<a href="./references#CD005425-bbs2-0005" title="SharmaM , NandN , AggarwalHK , NandD . Evaluation of effects of lovastatin on hypercholesterolaemia and renal functions in nephrotic syndrome. Indian Academy of Clinical Medicine2004;5(2):143‐6. ">Sharma 2004</a>). <a href="./references#CD005425-bbs2-0003" title="GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidaemia: A preliminary report. European Journal of Internal Medicine2009;20(3):e57–e61. [MEDLINE: 19393480] GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidaemia. Clinical &amp; Experimental Nephrology2008;12(3):189‐94. [MEDLINE: 18363032] ">Gheith 2009</a> (52 participants) reported statin treatment significantly increased serum albumin levels when compared to no treatment. There were no significant differences reported by the studies for total cholesterol, LDL cholesterol, triglycerides, SCr, BUN, or proteinuria between the statins and control group. There were no significant differences reported in total cholesterol, LDL cholesterol, HDL cholesterol, triglyceride, apoA, apoB, SCr, BUN, proteinuria, serum albumin, serum total protein between fibrates and placebo (<a href="./references#CD005425-bbs2-0001" title="BuyukcelikM , AnaratA , BayazitAK , NoyanA , OzelA , AnaratR , et al. The effects of gemfibrozil on hyperlipidaemia in children with persistent nephrotic syndrome. Turkish Journal of Pediatrics2002;44(1):40‐4. [MEDLINE: 11858378] ">Buyukcelik 2002</a>). All‐cause mortality, cardiovascular mortality, non‐fatal myocardial infarction, and stroke were not reported in any of the included studies. </p> <p>All studies reported adverse events. Three studies reported liver enzymes remained normal (no data provided) and one study (<a href="./references#CD005425-bbs2-0005" title="SharmaM , NandN , AggarwalHK , NandD . Evaluation of effects of lovastatin on hypercholesterolaemia and renal functions in nephrotic syndrome. Indian Academy of Clinical Medicine2004;5(2):143‐6. ">Sharma 2004</a>) reported one case of elevated liver enzymes in the statins group. Three studies reported CPK without providing data. One study reported CPK values fluctuated in both groups (<a href="./references#CD005425-bbs2-0004" title="OlbrichtCJ , WannerC , ThieryJ , BastenA . Simvastatin in nephrotic syndrome. Kidney International ‐ Supplement1999;56(Suppl 71):113‐6. [MEDLINE: 10412752] ">Olbricht 1999</a>) and the other studies reported normal levels (<a href="./references#CD005425-bbs2-0002" title="GheithO , SaadM , SobhM . Nephrotic dyslipidaemia, harvest of treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon (Portugal). 2004:258. GheithO , SobhM , GazarenS , AhmedH , ElBazM . Study the effect of treatment of nephrotic dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):100. GheithOA , SobhMA , MohamedKE , ElBazM , ElHusseiniF , GazarinSS , et al. Impact of treatment of dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron2002;91(4):612‐9. [MEDLINE: 12138263] ">Gheith 2002</a>) and no significant difference between the groups (<a href="./references#CD005425-bbs2-0003" title="GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidaemia: A preliminary report. European Journal of Internal Medicine2009;20(3):e57–e61. [MEDLINE: 19393480] GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidaemia. Clinical &amp; Experimental Nephrology2008;12(3):189‐94. [MEDLINE: 18363032] ">Gheith 2009</a>). There were no reported incidences of rhabdomyolysis. </p> </section> <section id="CD005425-sec-0091"> <h3 class="title" id="CD005425-sec-0091">Overall completeness and applicability of evidence</h3> <p>We identified a number of significant gaps in the evidence. We found no studies that compared ezetimibe, nicotinic acid, or bile acid sequestrants with placebo or no treatment. Only some of the many statin and fibrate preparations available were investigated; none compared one preparation with another. Poor reporting meant that issues concerning compliance and timing could not be elicited. Limited data meant that we were unable to incorporate histological and aetiological characteristics of nephrotic syndrome in our results. </p> <p>Supportive therapies were provided to participants in most studies, including administration of ACEi and corticosteriods, and restricting dietary cholesterol intake. </p> <p>Most participants had been diagnosed with primary nephrotic syndrome. However, it remains unknown if evidence from these patients can be extrapolated for people with secondary nephrotic syndrome. Comedications and nephrotic syndrome type may therefore be major issues to be considered around applicability of the evidence to clinical practice and patients. </p> </section> <section id="CD005425-sec-0092"> <h3 class="title" id="CD005425-sec-0092">Quality of the evidence</h3> <p><a href="#CD005425-fig-0002">Figure 2</a> and <a href="#CD005425-fig-0003">Figure 3</a> present the risk of bias summaries. The methodological quality of included studies was suboptimal. Although <a href="./references#CD005425-bbs2-0001" title="BuyukcelikM , AnaratA , BayazitAK , NoyanA , OzelA , AnaratR , et al. The effects of gemfibrozil on hyperlipidaemia in children with persistent nephrotic syndrome. Turkish Journal of Pediatrics2002;44(1):40‐4. [MEDLINE: 11858378] ">Buyukcelik 2002</a> was judged to be at low risk of bias for selection (allocation concealment), performance, detection and attrition bias, none of the included studies described random sequence generation, and all were judged to be at high risk for reporting bias. Since data were insufficient, synthesis was not undertaken for the majority of outcomes. With the exception of statins for three months and total cholesterol (<a href="./references#CD005425-bbs2-0003" title="GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidaemia: A preliminary report. European Journal of Internal Medicine2009;20(3):e57–e61. [MEDLINE: 19393480] GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidaemia. Clinical &amp; Experimental Nephrology2008;12(3):189‐94. [MEDLINE: 18363032] ">Gheith 2009</a>; <a href="./references#CD005425-bbs2-0005" title="SharmaM , NandN , AggarwalHK , NandD . Evaluation of effects of lovastatin on hypercholesterolaemia and renal functions in nephrotic syndrome. Indian Academy of Clinical Medicine2004;5(2):143‐6. ">Sharma 2004</a>), all other results were based on single study data. Although there was potential clinical heterogeneity in two studies, which may have been attributable to different use of statins (<a href="./references#CD005425-bbs2-0003" title="GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidaemia: A preliminary report. European Journal of Internal Medicine2009;20(3):e57–e61. [MEDLINE: 19393480] GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidaemia. Clinical &amp; Experimental Nephrology2008;12(3):189‐94. [MEDLINE: 18363032] ">Gheith 2009</a>; <a href="./references#CD005425-bbs2-0005" title="SharmaM , NandN , AggarwalHK , NandD . Evaluation of effects of lovastatin on hypercholesterolaemia and renal functions in nephrotic syndrome. Indian Academy of Clinical Medicine2004;5(2):143‐6. ">Sharma 2004</a>), data were synthesised. </p> </section> <section id="CD005425-sec-0093"> <h3 class="title" id="CD005425-sec-0093">Potential biases in the review process</h3> <p>The review was conducted according to a pre‐specified protocol. A comprehensive search strategy was used and main medical databases such as the Cochrane Renal Group's Specialised Register which contain the reports from many sources including non‐English journals were searched. Two authors selected studies independently using our prespecified inclusion criteria and screened study titles, abstracts and full texts to avoid selection bias. Quality assessment of studies was performed by two authors using the risk of bias assessment tool recommended by the Cochrane Collaboration. </p> <p>There have some limitations of this review; of the five studies included none reported all‐cause mortality and cardiovascular mortality. Data for some important outcomes were unavailable, for example, SD for serum cholesterol in <a href="./references#CD005425-bbs2-0002" title="GheithO , SaadM , SobhM . Nephrotic dyslipidaemia, harvest of treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon (Portugal). 2004:258. GheithO , SobhM , GazarenS , AhmedH , ElBazM . Study the effect of treatment of nephrotic dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):100. GheithOA , SobhMA , MohamedKE , ElBazM , ElHusseiniF , GazarinSS , et al. Impact of treatment of dyslipidaemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron2002;91(4):612‐9. [MEDLINE: 12138263] ">Gheith 2002</a>. Therefore data synthesis and subgroup analysis for most outcomes were not possible. Secondly, only two of the studies provided diagnostic criteria for nephrotic syndrome (<a href="./references#CD005425-bbs2-0001" title="BuyukcelikM , AnaratA , BayazitAK , NoyanA , OzelA , AnaratR , et al. The effects of gemfibrozil on hyperlipidaemia in children with persistent nephrotic syndrome. Turkish Journal of Pediatrics2002;44(1):40‐4. [MEDLINE: 11858378] ">Buyukcelik 2002</a>; <a href="./references#CD005425-bbs2-0004" title="OlbrichtCJ , WannerC , ThieryJ , BastenA . Simvastatin in nephrotic syndrome. Kidney International ‐ Supplement1999;56(Suppl 71):113‐6. [MEDLINE: 10412752] ">Olbricht 1999</a>). The definition of participants with nephrotic syndrome was crucial for the evaluation of curative effects. Furthermore, due to insufficient detailed information of the study process we judged for some risk of bias items as being 'unclear'. All the above may have contributed to potential biases. </p> </section> <section id="CD005425-sec-0094"> <h3 class="title" id="CD005425-sec-0094">Agreements and disagreements with other studies or reviews</h3> <p>We found no other systematic reviews investigating the use of lipid‐lowering agents in patients with nephrotic syndrome. <a href="./references#CD005425-bbs2-0024" title="Appel GB ,  Appel AS . Lipid‐lowering agents in proteinuric diseases. American Journal of Nephrology1990;10 Suppl 1:110‐5. [MEDLINE: 2256470] ">Appel 1990</a> reported that gemfibrozil decreased LDL cholesterol in people with nephrotic dyslipidaemia; however this was not the case in our review. <a href="./references#CD005425-bbs2-0024" title="Appel GB ,  Appel AS . Lipid‐lowering agents in proteinuric diseases. American Journal of Nephrology1990;10 Suppl 1:110‐5. [MEDLINE: 2256470] ">Appel 1990</a> also reported that HDL cholesterol was either increased or unchanged during statin treatment. One study in our review (<a href="./references#CD005425-bbs2-0005" title="SharmaM , NandN , AggarwalHK , NandD . Evaluation of effects of lovastatin on hypercholesterolaemia and renal functions in nephrotic syndrome. Indian Academy of Clinical Medicine2004;5(2):143‐6. ">Sharma 2004</a>) reported an increase in HDL cholesterol after lovastatin treatment. Lipid‐lowering agents had no effect on the degree of proteinuria. This was inconsistent with findings reported by <a href="./references#CD005425-bbs2-0003" title="GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidaemia: A preliminary report. European Journal of Internal Medicine2009;20(3):e57–e61. [MEDLINE: 19393480] GheithO , SheashaaH , AbdelsalamM , ShoeirZ , SobhM . Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidaemia. Clinical &amp; Experimental Nephrology2008;12(3):189‐94. [MEDLINE: 18363032] ">Gheith 2009</a> which indicated improvement in proteinuria in the statin group compared with no treatment. Although many studies have reported that statins confer favourable effects on total cholesterol and LDL cholesterol (<a href="./references#CD005425-bbs2-0031" title="European Association for Cardiovascular Prevention &amp; Rehabilitation, ReinerZ , CatapanoAL , DeBackerG , GrahamI , TaskinenMR , et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal2011;32(1):1769‐818. [MEDLINE: 21712404] ">ESC/EAS 2011</a>), we found no similar effects in people with nephrotic syndrome. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD005425-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/urn:x-wiley:14651858:media:CD005425:CD005425-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_t/tCD005425-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study selection flow diagram" data-id="CD005425-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study selection flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/full#CD005425-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005425-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/urn:x-wiley:14651858:media:CD005425:CD005425-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_t/tCD005425-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD005425-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/full#CD005425-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005425-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/urn:x-wiley:14651858:media:CD005425:CD005425-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_t/tCD005425-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD005425-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/full#CD005425-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005425-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/urn:x-wiley:14651858:media:CD005425:CD005425-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_t/tCD005425-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 1 Total cholesterol." data-id="CD005425-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 1 Total cholesterol. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/references#CD005425-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005425-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/urn:x-wiley:14651858:media:CD005425:CD005425-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_t/tCD005425-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 2 LDL cholesterol." data-id="CD005425-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 2 LDL cholesterol.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/references#CD005425-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005425-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/urn:x-wiley:14651858:media:CD005425:CD005425-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_t/tCD005425-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 3 HDL cholesterol." data-id="CD005425-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 3 HDL cholesterol.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/references#CD005425-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005425-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/urn:x-wiley:14651858:media:CD005425:CD005425-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_t/tCD005425-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 4 Triglyceride." data-id="CD005425-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 4 Triglyceride.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/references#CD005425-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005425-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/urn:x-wiley:14651858:media:CD005425:CD005425-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_t/tCD005425-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 5 Serum creatinine." data-id="CD005425-fig-0008" src="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 5 Serum creatinine. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/references#CD005425-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005425-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/urn:x-wiley:14651858:media:CD005425:CD005425-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_t/tCD005425-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 6 Blood urea nitrogen." data-id="CD005425-fig-0009" src="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 6 Blood urea nitrogen. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/references#CD005425-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005425-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/urn:x-wiley:14651858:media:CD005425:CD005425-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_t/tCD005425-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 7 Proteinuria." data-id="CD005425-fig-0010" src="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 7 Proteinuria.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/references#CD005425-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005425-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/urn:x-wiley:14651858:media:CD005425:CD005425-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_t/tCD005425-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 8 Serum albumin." data-id="CD005425-fig-0011" src="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 8 Serum albumin. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/references#CD005425-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005425-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/urn:x-wiley:14651858:media:CD005425:CD005425-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_t/tCD005425-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 9 Total serum protein." data-id="CD005425-fig-0012" src="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 9 Total serum protein. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/references#CD005425-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005425-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/urn:x-wiley:14651858:media:CD005425:CD005425-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_t/tCD005425-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 10 Apolipoprotein A." data-id="CD005425-fig-0013" src="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 10 Apolipoprotein A. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/references#CD005425-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005425-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/urn:x-wiley:14651858:media:CD005425:CD005425-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_t/tCD005425-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 11 Apolipoprotein B." data-id="CD005425-fig-0014" src="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 11 Apolipoprotein B. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/references#CD005425-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005425-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/urn:x-wiley:14651858:media:CD005425:CD005425-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_t/tCD005425-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 12 Elevated liver enzymes." data-id="CD005425-fig-0015" src="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 12 Elevated liver enzymes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/references#CD005425-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005425-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/urn:x-wiley:14651858:media:CD005425:CD005425-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_t/tCD005425-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 13 Alanine aminotransferase." data-id="CD005425-fig-0016" src="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 13 Alanine aminotransferase. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/references#CD005425-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005425-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/urn:x-wiley:14651858:media:CD005425:CD005425-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_t/tCD005425-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 14 Aspartate aminotransferase." data-id="CD005425-fig-0017" src="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 14 Aspartate aminotransferase. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/references#CD005425-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005425-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/urn:x-wiley:14651858:media:CD005425:CD005425-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_t/tCD005425-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 15 Creatine phosphokinase." data-id="CD005425-fig-0018" src="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Lipid‐lowering agents versus placebo or no treatment, Outcome 15 Creatine phosphokinase. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/references#CD005425-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/media/CDSR/CD005425/image_n/nCD005425-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="comparison" data-id="CD005425-tbl-0001"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Lipid‐lowering agents versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Statins (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐53.04 [‐159.53, 53.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Statins (6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐45.0 [‐144.57, 54.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Statins (1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐46.0 [‐144.26, 52.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Fibrates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>42.0 [‐33.63, 117.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 LDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Fibrates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 HDL cholesterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Fibrates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Triglyceride <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Fibrates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Statins (3 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Statins (6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Statins (1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Fibrates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Blood urea nitrogen <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Fibrates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Proteinuria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Fibrates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Serum albumin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Statins (6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Statins (1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Fibrates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Total serum protein <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Fibrates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Apolipoprotein A <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Fibrates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Apolipoprotein B <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Fibrates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Elevated liver enzymes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Alanine aminotransferase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Fibrates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Aspartate aminotransferase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Fibrates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Creatine phosphokinase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Fibrates</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Lipid‐lowering agents versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005425.pub2/references#CD005425-tbl-0001">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD005425.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD005425-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD005425-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD005425-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD005425-note-0001">Bahasa Malaysia</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br/> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005425\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005425\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005425\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005425\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005425\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005425\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005425\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005425\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005425\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005425\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005425\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005425\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005425\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005425\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005425\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005425\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005425\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005425\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=VXKc2U6b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005425.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005425.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD005425.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD005425.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005425.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716352219"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005425.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716352222"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005425.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d9d68a97d9368',t:'MTc0MDcxNjM1Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 